AMERICAN MADE SINCE 1973 OBCI, INC. ANNUAL REPORT 2017 Fellow Shareholders:
Last year was an extraordinary year for both our company and our country. Through the many
natural disasters we experienced—hurricanes, floods, winter storms—we still see the spirit of
perseverance across the nation. Recreational boating is up, fuel prices are down, and people
are traveling in RVs like never before.
This has been great for our company. As Ocean Bio-Chem, Inc. enters into its 45th year of operating,
I am pleased to report both record net sales and record profits for 2017. Our company earned
a record $2.6 million in net income on revenue of $38.9 million—an increase of approximately
24% over 2016 earnings. In fact, we have delivered record
results for the last five years, and we hope to continue to
deliver in the future.
PRODUCT INITIATIVES
Last year was a revolutionary year for OdorStar/
Performacide® products in many ways. First, we branded
Performacide® Kills Parvo™ for the pet market. We are
built for success in the pet industry: the sales channels
greatly mimic the marine market we know so well and
excel at. Distribution, wholesale, and retail all saw double-
digit growth percentages. Second, in the aftermath of
Hurricane Harvey, the trusted power of Performacide
mold and mildew products helped with the clean-up and
restoration of flood-damaged property. And third, our
line of ClO2 gas products—branded as NosGUARDSG—
“
Despite the challenges
faced by many brick
and mortar stores,
Ocean Bio-Chem
continued to increase
sales in a variety of
retail channels, enabling
us to realize record net
sales in 2017.
Peter Dornau
President & CEO
”
has taken off in the auto industry, realizing major retail distribution. Overall, we see the
opportunities for and interest in Performacide growing sharply as a result of key decisions and
wise marketing efforts that will support even more growth throughout the years to come.
Star Tron® continues its success as the top-selling enzyme fuel treatment. Hurricanes and
winter storms had many Americans firing up generators, relying on Star Tron for an effortless
start-up. Also, sport fishing in the U.S. is evolving; many of our longtime pro Anglers are gaining
greater viewership and moving to network TV, bringing Star Tron to a much wider, youthful,
and new audience. With exciting product developments on the horizon in 2018, coupled with
impactful marketing and advertising presence, we foresee another great year.
Other targeted initiatives include successes achieved in national hardware chains, growth in
the booming DIY agricultural market, and great movement with RVs and powersports.
Of course, our core is and always will be the marine market. As the sales of new boats strengthen,
our core line of Star brite® marine products remains solid. The rebranding and reformulation of
many of our top selling marine chemicals into the Star brite Ultimate line has proven incredibly
successful and continues to be a top seller in retailers both nationally and internationally.
AMERICAN MADE SINCE 1973
PLANT EXPANSION
The economy is growing, and with it, OBCI. We have become a trusted name for American-
made private label, blending, and manufacturing. As business continues to expand, we’re
preparing for our expected growth: expanding our capabilities and, above all, maximizing
our efficiency.
With that, we are excited to announce the completion of our 85,000-square-foot addition,
increasing our manufacturing, warehouse and distribution capacities of our subsidiary,
Kinpak, Inc., in Montgomery, Alabama. In total, after this third phase of expansion is complete,
we now have approximately 300,000-square-feet for manufacturing at Kinpak. We also
increased the outdoor tank farm to accommodate an additional 500,000 gallons of capacity,
doubling the current capacity and increasing storage for bulk blends and finished products.
The total investment in our facilities for all three phases of the expansion will be approximately
$6 million, with both the City of Montgomery and State of Alabama providing significant
monetary incentives.
BALANCE SHEET/SPECIAL DIVIDEND
The Company continues to have a strong balance sheet. We ended 2017 with a current ratio
of over 7.6 to 1 and approximately $24.9 million of shareholder’s equity and over $5.2 million in
total cash. The Board of Directors declared a special cash dividend of $0.06 per share payable
to shareholders of record on April 16, 2018.
OUTLOOK
The year 2018 is a milestone for Ocean Bio-Chem., Inc. The Company is celebrating its 45th
anniversary in business this year, as well as 40 years listed on the NASDAQ Capital Market
stock exchange.
The investment commitment in our plant expansion is critical for our continued growth in the
future. All economic indicators support our optimism that 2018 will be another successful year
for the Company financially. We are well-positioned to benefit from the strong economy, lower
unemployment, low interest rate and fuel costs, and the renewed commitment and national
support of American-made goods.
In closing, I would like to express my sincere gratitude and appreciation to all Ocean Bio-Chem,
Inc. employees for their continued dedication and hard work. We are also very thankful for the
support of all of our customers, suppliers and shareholders, and excited about the year ahead
as we turn forty-five.
Peter G. Dornau
President and Chief Executive Officer
April, 2018
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 1
03/30/2018 02:52 PM
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2017
or
For the transition period from _______ to _______
Commission File Number 000-11102
OCEAN BIO-CHEM, INC.
(Exact name of registrant as specified in its charter)
Florida
(State or other jurisdiction of
incorporation or organization)
59-1564329
(I.R.S. Employer
Identification No.)
4041 SW 47 AVENUE
FORT LAUDERDALE, FLORIDA 33314
(Address of principal executive offices)
954-587-6280
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, $0.01 par value
Name of each exchange on which registered
The NASDAQ Stock Market
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether registrant has submitted electronically and posted on its corporate Web site, if any every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to
submit and post such files). Yes ☒ No ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best
of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Non-accelerated filer
☐
☐
Accelerated filer
Smaller reporting company
Emerging growth company
☐
☒
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
The aggregate market value of the Common Stock held by non-affiliates of the registrant at June 30, 2017 was $12,234,396, based upon the closing price of
the registrant’s common stock on the NASDAQ Capital Market. For purposes of making this computation only, all executive officers, directors and
beneficial owners of more than five percent of the registrant’s Common Stock are deemed to be affiliates.
At March 29, 2018, 9,254,580 shares of the registrant’s Common Stock were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement, which will be filed not later than April 30, 2018, are incorporated by reference in Part III of this
report.
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 2
03/30/2018 02:52 PM
OCEAN BIO-CHEM, INC.
TABLE OF CONTENTS
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures about Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
Exhibits, Financial Statement Schedules
Form 10-K Summary
Part I
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4
Part II
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Part III
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Part IV
Item 15.
Item 16
Signatures
Index To Consolidated Financial Statements
Forward-looking Statements:
Page
1
4
5
5
5
5
6
6
6
11
11
11
11
11
12
12
12
12
12
13
13
14
F-1
Certain statements contained in this Annual Report on Form 10-K, including without limitation, the anticipated time of completion of the expansion of our
manufacturing and warehouse facilities; our ability to locate substitute manufacturing facilities in the event arrangements with any third party manufacturer
are discontinued; our ability to renew or replace our revolving credit facility; anticipated relocation of our fabrication and assembly operations relating to
brushes used for cleaning boats, automobiles and recreational vehicles; our ability to provide required capital to support inventory levels; the effect of price
increases in raw materials that are petroleum or chemical based or commodity chemicals on our margins; and the sufficiency of funds provided through
operations and existing sources of financing to satisfy our cash requirements constitute forward-looking statements. For this purpose, any statements
contained in this report that are not statements of historical fact may be deemed forward-looking statements. Without limiting the generality of the foregoing,
words such as “believe,” “may,” “will,” “expect,” “anticipate,” “intend,” or “could,” including the negative or other variations thereof or comparable
terminology, are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which
may cause actual results to be materially different from those expressed or implied by such forward-looking statements. Factors that may affect these results
include, but are not limited to, unanticipated delays in completion of the expansion of our manufacturing and warehouse facilities; the highly competitive
nature of our industry; reliance on certain key customers; changes in consumer demand for marine, recreational vehicle and automotive products; advertising
and promotional efforts; exposure to market risks relating to changes in interest rates, foreign exchange rates, prices for raw materials that are petroleum or
chemical based and other factors discussed below under Item 1A, “Risk Factors.”
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 3
03/30/2018 02:52 PM
Item 1. Business
General:
PART I
We are principally engaged in the manufacture, marketing and distribution of a broad line of appearance, performance and maintenance products for the
marine, automotive, power sports, recreational vehicle and outdoor power equipment markets, under the Star brite® and Star Tron® brand names. We sell
these products within the United States of America and Canada. In addition, we produce private label formulations of many of our products for various
customers and provide custom blending and packaging services for these and other products. We also manufacture, market and distribute disinfectant,
sanitizing and deodorizing products under the Performacide® and Star brite® brand names, utilizing a patented delivery system for use with products
containing chlorine dioxide. Unless the context indicates otherwise, we sometimes refer to Ocean Bio-Chem, Inc. and its consolidated subsidiaries as “the
Company,” “we” or “our.”
Ocean Bio-Chem, Inc. was incorporated in 1973 under the laws of the state of Florida. In 1981, we purchased, from Peter G. Dornau and Arthur Spector, the
co-founders of the Company, rights to the Star brite® trademark and related products for the United States and Canada. Mr. Dornau, our Chairman,
President and Chief Executive Officer, has retained rights to these assets with respect to all other geographic areas. Accordingly, products we manufacture
that are sold outside of the United States and Canada are purchased from us and distributed by two companies owned by Mr. Dornau. Net sales to the two
companies in 2017 and 2016 totaled approximately $2,070,000 and $1,850,000 or 5.3% and 5.1% of our net sales, respectively. See Note 9 to the
consolidated financial statements included in this report for additional information.
Because our operations involve, in all material respects, substantially similar manufacturing and distribution processes, our operations constitute one
reportable segment for financial reporting purposes.
Recent Developments:
We are nearing completion of a project involving expansion of the manufacturing, warehouse and distribution facilities of our subsidiary, KINPAK Inc.
(“Kinpak”) in Montgomery, Alabama (the “Expansion Project”). The Expansion Project principally entails an approximately 85,000 square feet addition to
the facilities and an expansion of Kinpak’s outdoor tank farm to accommodate an additional 500,000 gallons in tank capacity. The addition to the facilities
and expansion of the tank farm are completed. The remaining parts of the Expansion Project involve additional upgrades to warehouse facilities and
installation of new manufacturing equipment. At December 31, 2017, expenditures in connection with the Expansion Project aggregated approximately $5.1
million, and we estimate that the total cost of the Expansion Project will be approximately $6.0 million. The Expansion Project is expected to be completed
and placed into service during 2018. Most of the Expansion Project is being financed with the proceeds of an industrial development bond financing,
described in Note 6 to the consolidated financial statements included in this report.
Products:
The products that we manufacture and market include the following:
Marine: Our marine line consists of polishes, cleaners, protectants and waxes under the Star brite® brand name, enzyme fuel treatment under the Star Tron®
brand name, and private label products sold by some of our customers. The marine line also includes motor oils, boat washes, vinyl cleaners, protectants,
teak cleaners, teak oils, bilge cleaners, hull cleaners, silicone sealants, polyurethane sealants, polysulfide sealants, gasket materials, lubricants, antifouling
additives and anti-freeze coolants. In addition, we manufacture a line of brushes, poles, tie-downs and other related marine accessories.
Automotive: We manufacture a line of automotive products under the Star brite® and Star Tron® brand names The automotive line includes fuel treatments
for both gas and diesel engines, motor oils, greases and related items. Our Star Tron® enzyme fuel treatment is designed to eliminate and prevent engine
problems associated with fuel containing 10% ethanol (E-10 fuel) including, among other things, fuel degradation, debris in fuel (gum and varnish formation)
and ethanol’s propensity to attract water (which can adversely affect octane). Star Tron® fuel treatment also increases fuel economy by cleaning the fuel
delivery system and facilitating more complete and uniform combustion. In addition, we produce anti-freeze and windshield washes under the Star brite®
brand and under private labels for customers. We also produce automotive polishes, cleaners and other appearance items.
1
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 4
03/30/2018 02:52 PM
Recreational Vehicle/Power Sports: We market Star Tron® fuel treatment and other specialty products to the recreational vehicle market, including snow
mobiles, all-terrain vehicles and motorcycles. For power sports enthusiasts, Star Tron® provides a viable solution to a number of problems associated with
E-10 fuel. Other specialty recreational vehicle/power sports products include cleaners, polishes, detergents, fabric cleaners and protectants, silicone sealants,
waterproofers, gasket materials, degreasers, vinyl cleaners and protectants, toilet treatment fluids and anti-freeze/coolant.
Outdoor Power Equipment/ Lawn & Garden: We market Star Tron® as a solution to help rectify a number of operating engine problems associated with
E-10 fuel in commercial lawn equipment and other home and garden power equipment.
Disinfectants, Sanitizers and Deodorizers: Our line of disinfectant, sanitizing and deodorizing products are marketed under the Performacide® and Star brite®
brand names. Performacide® products include disinfectants for hard, non-porous surfaces, air care products for deodorizing and products to eliminate mold
and mildew. The U.S. Environmental Protection Agency has accepted labeling for Performacide® used in hard surface applications that claims, among other
things, effectiveness as a virucide against a variety of viruses, including HIV-1, Influenza-A, Herpes Simplex-2, Poliovirus-1 norovirus and rotavirus; as a
disinfectant against a number of different types of bacteria; and as a sanitizer against certain types of bacteria that cause food borne illnesses. We are
directing distribution efforts principally towards the marine, automotive, home restoration, law enforcement and agriculture markets, and to institutions such
as schools.
Contract Filling and Blow Molded Bottles: We blend and package a variety of chemical formulations to our customers’ specifications. In addition, we
manufacture for sale to various customers assorted styles of both PVC and HDPE blow molded bottles.
Manufacturing: We produce the majority of our products at Kinpak’s manufacturing facilities in Montgomery, Alabama. In addition, we contract with
various third party manufacturers to manufacture some of our products, which are manufactured to our specifications using our provided formulas. Each
third party manufacturer enters into a confidentiality agreement with us.
We purchase raw materials from a variety of suppliers; all raw materials used in manufacturing are readily available from alternative sources. We design our
own packaging and supply our outside manufacturers with the appropriate design or packaging. We believe that our internal manufacturing capacity and our
arrangements with our current outside manufacturers are adequate for our present needs.
In the event that arrangements with any third party manufacturer are discontinued, we believe that we will be able to locate substitute manufacturing facilities
without a substantial adverse effect on our manufacturing and distribution.
Marketing and Significant Customers: Our branded and private label products are sold through national retailers such as Wal-Mart, Tractor Supply, West
Marine and Bass Pro Shops. Additionally, we market our products via online retailers. We also sell to national and regional distributors that resell our
products to specialized retail outlets. In the case of Performacide® disinfectant/sanitizing products, we sell to distributors that resell our products, in some
cases under private labels, to end users principally in the marine, automotive, home restoration, law enforcement and agriculture markets.
Net sales to each of two customers exceeded 10% of our consolidated net sales, and in the aggregate constituted approximately 34.0% and 33.0% of our
consolidated net sales for the years ended December 31, 2017 and 2016, respectively. Net sales to our five largest unaffiliated customers for the years ended
December 31, 2017 and 2016 amounted to approximately 52.2% and 48.8% of our consolidated net sales, respectively, and at December 31, 2017 and 2016,
outstanding accounts receivable balances from our five largest unaffiliated customers aggregated approximately 50.9% and 36.0% of our consolidated
accounts receivable, respectively.
We market our products through both internal salesmen and external sales representatives who work on an independent contractor commission basis. Our
personnel also participate in sales presentations and trade shows. In addition, we market our brands and products through advertising campaigns in national
magazines, on television, on the internet, in newspapers and through product catalogs. Our products are distributed primarily from Kinpak’s manufacturing
and distribution facility in Montgomery, Alabama. Since 2008, we have participated in a vendor managed inventory program with one major customer. See
Note 2 to the consolidated financial statements included in this report for additional information.
Backlog, seasonality, and selling terms: We had no significant backlog of orders at December 31, 2017. We generally do not give customers the right to
return products. The majority of our products is non-seasonal and is sold throughout the year. Normal trade terms offered to customers range from 30 to 180
days. However, at times we offer extended payment terms or discount arrangements as purchasing incentives to customers. Historically, these initiatives
have not materially affected our overall profit margins.
Competition:
Competition with respect to our principal product lines is described below. The principal elements of competition affecting all of our product lines are brand
recognition, price, service and the ability to deliver products on a timely basis.
Marine: We have several national and regional competitors in the marine marketplace. We do not believe that any competitor or small group of competitors
hold a dominant market share. We believe that we can increase or maintain our market share through expenditures directed to our present advertising and
distribution channels.
2
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 5
03/30/2018 02:52 PM
Automotive: There are a large number of companies, both national and regional, that compete with us. Many are more established and have greater financial
resources than we do. While our market share is small, the total market size is substantial. We believe that we have established a reasonable market share
through our present advertising and distribution channels, considering the large size of this market.
Recreational Vehicle/Power Sports: We compete with national and regional competitors. We do not believe that any competitor or small group of
competitors hold a dominant market share. We believe that we can increase or maintain our market share by utilizing advertising and distribution channels
similar to those we use in the marine market.
Outdoor Power Equipment/Lawn & Garden: We compete with several established national and regional competitors. We do not believe that any competitor
or small group of competitors hold a dominant market share. We have attempted to make inroads in this market by emphasizing Star Tron®’s unique
formulation and by increasing our advertising and attendance at trade shows.
Disinfectants, Sanitizers and Deodorants: There are a large number of companies that compete with us, many of which are much larger, and have much
greater financial resources than we do. We emphasize the effectiveness of chlorine dioxide, coupled with the convenience in application of our
Performacide® products.
Trademarks: We have obtained registered trademarks for Star brite®, Star Tron®, Performacide® and other trade names used on our products. We view
our trademarks as significant assets because they provide product recognition. We believe that our trademarks provide protection in the geographic markets
we serve, but we cannot assure that our intellectual property rights can be successfully asserted in the future or will not be invalidated, circumvented or
challenged.
Patents: We own several patents, the most significant of which relate to a delivery system for use with products containing chlorine dioxide (the “ClO2
Patents”). The ClO2 patents expire in 2022. We have encountered difficulty in protecting the ClO2 patents through litigation. See “Risk Factors - If we do
not utilize or successfully assert intellectual property rights, our competitiveness could be materially adversely affected,” in Item 1A of this report for
additional information. A 2014 adverse judgment in patent litigation that was upheld on appeal in 2015 has limited the scope of protection provided by the
patent. To date, we do not believe the judgment has materially impaired our ability to effectively market and distribute our Performacide® products.
However, we are unable to predict the long-term competitive effect of the judgment on these products.
New Product Development: We continue to develop specialized products for the marine, automotive, recreational vehicle/power sports and outdoor power
equipment/lawn and garden markets. Expenditures for new product development have not been significant and are charged to operations in the year incurred.
Personnel: At December 31, 2017, we had 140 full-time employees and two part-time employees who constituted one full-time equivalent. The following
table provides information regarding personnel working for the Company and its subsidiaries at December 31, 2017:
Location
Fort Lauderdale, Florida
Fort Lauderdale, Florida
Montgomery, Alabama
Description
Administrative, sales, and marketing
Manufacturing and distribution
Manufacturing and distribution
Number of
Employees
44
6
92*
142
* Includes two part-time employees, who constitute one full-time equivalent.
3
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 6
03/30/2018 02:52 PM
Item 1A. Risk Factors
If we do not compete effectively, our business will suffer.
We confront aggressive competition in the sale of our products. In each of the markets in which we sell our products, we compete with a number of national
and regional competitors. Competition in the automotive market is particularly intense, with many national and regional companies marketing competitive
products. Many of our competitors in the automotive market are more established and have greater financial resources than we do. Moreover, we confront
intense competition with respect to our Performacide® disinfectant, sanitizing and deodorizing products from a large number of competitors, many of which
are well established and have substantially greater financial resources than we do. Our inability to successfully compete in our principal markets would have
a material adverse effect on our financial condition, results of operations and cash flows.
Our business is, to a significant extent, dependent on a small number of major customers, and the loss of any of these customers could adversely
affect our financial condition, results of operations and cash flows.
Net sales to our five largest unaffiliated customers accounted for 52.2% of our consolidated net sales in 2017; the two largest unaffiliated customers
accounted for 34.0% of our consolidated net sales in 2017. The loss of any of these customers would have a material adverse effect on our financial
condition, results of operations and cash flows.
Our Chairman, President and Chief Executive Officer is a majority shareholder who controls us, and his interests may conflict with or differ from
the Company’s interests.
Peter G. Dornau, our Chairman, President and Chief Executive Officer, together with a family entity he controls, owns approximately 51.4% of our Common
Stock. As a result, Mr. Dornau has the power to elect all of our directors and effectively has the ability to prevent any transaction that requires the approval
of our Board of Directors and our shareholders. Products that we manufacture and that are sold outside of the United States and Canada are purchased from
us and distributed by two companies owned by Mr. Dornau, which we refer to as the “affiliated companies.” The affiliated companies also collectively own
the rights to the Star brite® and Star Tron® trademarks and related products outside of the United States and Canada. Sales to the affiliated companies
aggregated approximately $2,070,000 and $1,850,000 during the years ended December 31, 2017 and 2016, respectively. In addition, we provided
administrative services to the affiliated companies for fees aggregating approximately $884,000 and $735,000 (including $120,000 and $115,000 to
reimburse the Company for business related expenditures that we made on behalf of the affiliated companies) during the years ended December 31, 2017 and
2016, respectively. Receivables due from the affiliated companies in connection with product sales and administrative services totaled approximately
$1,584,000 and $1,190,000 at December 31, 2017 and 2016, respectively. The accounts receivable turnover ratio for the year ended December 31, 2017 with
respect to sales to the affiliated companies was approximately 3.3 and with respect to administrative services was approximately 1.1. Management believes
that the sales and provision of administrative services to the affiliated companies do not involve more than normal credit risk.
We have entered into other transactions with entities owned by Mr. Dornau. See Notes 9 and 10 to the consolidated financial statements included in this
report for additional information.
Economic conditions can adversely affect our business.
We are subject to risks arising from adverse changes in general domestic and global economic conditions, including recession or economic slowdown and
disruption of credit markets, which may impair the ability of our customers to satisfy obligations due to us. In addition, we believe that adverse economic
conditions in recent years adversely constrained discretionary spending, which we believe has, at times, adversely affected our product lines, particularly
those directed to the marine and recreational vehicle markets. While published reports indicate that economic conditions recently have improved both
domestically and globally, a future decline in economic conditions could have a material adverse effect on our financial condition, results of operations and
cash flows.
If we do not effectively utilize or successfully assert intellectual property rights, our competiveness could be materially adversely affected.
We rely on trademarks and trade names in connection with our products, the most significant of which are Star brite® and Star Tron®. In addition, we own
patents we have viewed as providing some degree of competitive support for our Performacide® products. We rely on trademark, trade secret, patent and
copyright laws to protect our intellectual property rights. We cannot assure that these intellectual property rights will be effectively utilized or, if necessary,
successfully asserted. There is a risk that we will not be able to obtain and perfect our own intellectual property rights, or, where appropriate, license from
others intellectual property rights necessary to support new product introductions. Our intellectual property rights, and any additional rights we may obtain in
the future, may be invalidated, circumvented or challenged in the future, and the legal costs necessary to protect our intellectual property rights could be
significant. In this regard, in 2013, we filed a patent infringement lawsuit in the United States District Court for the Southern District of Florida with respect
to a U.S. patent relating to a delivery system for use with products containing chlorine dioxide, but the District Court granted the defendants’ motion for
summary judgment, which the Federal Circuit Court of Appeals affirmed in January 2015. As a result, in March 2015, we stipulated to the dismissal with
prejudice of our patent infringement claims in another lawsuit related to the same patent, and, in response, the court dismissed our claims. We are unable to
predict the long-term competitive effect of the adverse outcome in the patent litigation on our Performacide® products. Our failure to perfect or successfully
assert intellectual property rights could harm our competitive position and could have a material adverse effect on our financial condition, results of
operations and cash flows.
4
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 7
03/30/2018 02:52 PM
Environmental matters may cause potential liability risks.
We must comply with various environmental laws and regulations in connection with our operations, including those relating to the handling and disposal of
hazardous wastes and the remediation of contamination associated with the use and disposal of hazardous substances. A release of such substances due to
accident or intentional act could result in substantial liability to governmental authorities or to third parties. In addition, we are subject to reporting
requirements with respect to certain materials we use in our manufacturing operations. In January 2011, Kinpak, which owns our manufacturing facility in
Montgomery, Alabama, became subject to a consent agreement and final order with the United States Environmental Protection Agency relating to its
alleged failure to complete and submit certain required forms with respect to toxic and hazardous chemicals used at its facilities. Under the consent
agreement and final order, Kinpak paid a civil penalty of $110,000. It is possible that we could become subject to additional environmental liabilities in the
future that could have a material adverse effect on our business, financial condition, results of operations and cash flows.
Our variable rate indebtedness exposes us to risks related to interest rate fluctuation and matures in August 2018.
We have a revolving line of credit with a variable interest rate. Interest on the revolving line of credit is payable at the one month LIBOR rate plus 1.50% per
annum, computed on a 365/360 basis. At December 31, 2017, we did not have any borrowings outstanding under the revolving line of credit. However, if
we borrow amounts under the revolving line of credit in the future, and if interest rates were to increase significantly, our financial condition, results of
operations and cash flows could be materially adversely affected. Moreover, we believe, but cannot assure, that we could obtain a renewal of the revolving
line of credit or a suitable replacement facility when the current facility terminates in August 2018. Our failure to renew or obtain a replacement for our
current facility may impair our financial flexibility and have a material adverse effect on our business.
Trading in our Common Stock has been limited, and our stock price could potentially be subject to substantial fluctuations.
Our common stock is listed on the NASDAQ Capital Market, but trading in our stock has been limited. Our stock price could be affected substantially by a
relatively modest volume of transactions.
Item 1B. Unresolved Staff Comments
Not applicable.
Item 2. Properties
Our executive offices and one of our manufacturing facilities are located in Fort Lauderdale, Florida and are leased from an entity controlled by our
Chairman, President and Chief Executive Officer. The lease covers approximately 12,700 square feet of office, manufacturing, and warehouse space. The
lease expires in December 2023. See Note 10 to the consolidated financial statements included in this report for additional information.
Kinpak leases its Alabama manufacturing facilities from The Industrial Development Board of the City of Montgomery, Alabama (the “IDB”). Kinpak
entered into the lease in its current form in connection with an industrial development bond financing related to the Expansion Project; Kinpak’s lease
payments are used to fund repayment of the IDB’s obligations under the bond it issued in connection with the industrial development bond financing. See
Note 6 to the consolidated financial statements included in this report for additional information. Under the lease, prior to the maturity date of the bond,
Kinpak may repurchase the facilities for $1,000 if the bond has been redeemed or fully paid. The facilities currently (without giving effect to the Expansion
Project) contain approximately 187,000 square feet of office, plant and warehouse space on 20 acres of land. As discussed above in Item 1, Recent
Developments, we are nearing completion of the Expansion Project.
In addition, we lease a 15,000 square foot warehouse in Montgomery, Alabama, near the Kinpak manufacturing facility. We use the warehouse to fabricate
and assemble brushes used for cleaning boats, automobiles and recreational vehicles. The lease expires in July 2018. We plan to relocate the fabrication and
assembly operations with respect to the brushes to the expanded Kinpak manufacturing facilities prior to expiration of the lease.
Item 3. Legal Proceedings
Not applicable
Item 4. Mine Safety Disclosures
Not applicable.
5
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 8
03/30/2018 02:52 PM
Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is traded on the NASDAQ Capital Market under the symbol OBCI. A summary of the high and low sales prices during each quarter of
2017 and 2016 is presented below.
PART II
2017
2016
High
Low
High
Low
1st Qtr.
2nd Qtr.
3rd Qtr.
4th Qtr.
$
$
$
$
5.15
3.66
2.66
1.93
$
$
$
$
5.65
3.69
2.57
2.08
$
$
$
$
5.47
3.51
3.17
2.02
$
$
$
$
5.71
3.98
4.35
2.61
On December 31, 2017, there were 112 holders of record. Because many of our shares are held by brokers and institutions on behalf of shareholders, we are
unable to estimate the total number of shareholders represented by these record holders.
On April 13, 2017, the Board of Directors of Ocean Bio-Chem, Inc. declared a special dividend of $0.06 per share payable on May 11, 2017 to shareholders
of record on April 27, 2017.
On March 25, 2016, the Board of Directors of Ocean Bio-Chem, Inc. declared a special dividend of $0.06 per share payable on April 26, 2016 to
shareholders of record on April 12, 2016.
Payment of dividends in the future will be subject to the discretion of the Board of Directors in light of numerous factors, including the Company’s business
performance and operating plans, capital commitments, liquidity and other factors.
Item 6. Selected Financial Data
Not applicable.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our consolidated financial statements contained in Item 8 of this report.
Overview:
We are engaged in the manufacture, marketing and distribution of a broad line of appearance, performance, and maintenance products for the marine,
automotive, power sports, recreational vehicle and outdoor power equipment markets, under the Star brite® and other trademarks within the United States
and Canada. In addition, we produce private label formulations of many of our products for various customers and provide custom blending and packaging
services for these and other products. We also manufacture, market and distribute a line of products including disinfectants, sanitizers and deodorizers. We
sell our products through national retailers and to national and regional distributors. In addition, we sell products to two companies affiliated with Peter G.
Dornau, our Chairman, President and Chief Executive Officer; these companies distribute the products outside of the United States and Canada. Transactions
with the affiliated companies were made in the ordinary course of business, and management believes that sales to the affiliated companies do not involve
more than normal credit risk.
We are nearing completion of the Expansion Project, which involves the expansion of Kinpak’s manufacturing and warehouse facilities in Montgomery,
Alabama. See “Business - Recent Developments” in Item 1 of this report for additional information.
The Tax Cuts and Jobs Act, which was enacted on December 22, 2017, changes United States tax law significantly. The most important change affecting
Ocean Bio-Chem, Inc. is the reduction in the United States corporate income tax rate from 35% to 21%, effective January 1, 2018. Among other things, the
reduction in the corporate tax rate resulted in a substantial decrease in our deferred tax liabilities, which is discussed in more detail below under “Results of
Operations – Provision for income taxes.”
6
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 9
03/30/2018 02:52 PM
Our operating results for 2016 were adversely affected by professional fees and expenses related to litigation against a competitor in which we and the
competitor each claimed that the other was engaged in false advertising and related violations of law (the “Advertising Litigation”). Following a trial in
which it was determined that neither party was liable to the other, the Advertising Litigation was concluded. Our professional fees and expenses related to the
Advertising Litigation were approximately $1,146,000 in 2016. As the Advertising Litigation was concluded in 2016, we had no expenses related to the
Advertising Litigation during 2017.
Critical accounting estimates:
The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those
estimates and assumptions.
We have identified the following as critical accounting estimates, which are defined as those that are reflective of significant judgments and uncertainties, are
the most pervasive and important to the presentation of our financial condition and results of operations and, if subject to different assumptions and
conditions, could lead to materially different results.
Collectability of trade accounts receivable
In the ordinary course of business, we grant non-interest bearing trade credit to our unaffiliated customers on terms that range from 30 to 180 days. In an
effort to reduce our credit risk, we perform ongoing credit evaluations of our customers and adjust credit limits based upon payment history and aging of
receivables, as well as our customers’ creditworthiness, as determined by our review of their current credit information. We generally do not require
collateral on trade accounts receivable. We maintain an allowance for doubtful accounts based on expected collectability of the trade accounts receivable,
after considering our historical collection experience, the length of time an account is outstanding, the financial position of the customer if known and
information provided by credit rating services. The adequacy of this allowance is reviewed each reporting period and adjusted as necessary. Our allowance
for doubtful accounts was approximately $79,000 and $75,000 at December 31, 2017 and 2016, respectively, which was approximately 1.6% and 1.5% of
gross accounts receivable at December 31, 2017 and 2016, respectively. If the financial condition of our customers were to deteriorate, resulting in increased
uncertainty as to their ability to make payments, or if unexpected events or significant future changes in trends were to occur, we may be required to increase
the allowance or incur a bad debt expense. In this regard, we incurred a bad debt expense of approximately $199,000 in 2017, most of which resulted from a
customer’s bankruptcy.
Inventories
Our inventories primarily are composed of raw materials and finished goods and are stated at the lower of cost or net realizable value, using the first-in, first-
out method. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal
and transportation. We maintain a reserve for slow moving and obsolete inventory to reflect the diminution in value resulting from product obsolescence,
damage or other issues affecting marketability in an amount equal to the difference between the cost of the inventory and its estimated net realizable
value. The adequacy of this reserve is reviewed each reporting period and adjusted as necessary. We regularly compare inventory quantities on hand against
historical usage or forecasts related to specific items in order to evaluate obsolescence and excessive quantities. In assessing historical usage, we also
qualitatively assess business trends to evaluate the reasonableness of using historical information as an estimate of future usage.
Our slow moving and obsolete inventory reserve was $274,295 and $268,159 at December 31, 2017 and 2016, respectively.
Income taxes
We account for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized to reflect the future
tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax
bases. Deferred tax assets and liabilities are measured and recorded using currently enacted tax rates, which we expect will apply to taxable income in the
years in which the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases are recovered or
settled. The differences are attributable to differing methods of financial statement and income tax treatment with respect to depreciation and reserves for
trade accounts receivable and inventories. The likelihood of a material change in our expected realization of deferred tax assets is dependent on, among other
factors, changes in tax law, future taxable income and settlements with tax authorities. In this regard, the enactment of the Tax Cuts and Jobs Act resulted in
a meaningful reduction in our net deferred tax liability as of December 31, 2017, reflecting the Tax Cuts and Jobs Act’s reduction of the United States
corporate income tax rate. While management believes that its judgments and interpretations regarding income taxes are appropriate, significant differences
in actual experience may require future adjustments to our tax assets and liabilities, which could be material.
In assessing the realizability of our deferred tax assets, we evaluate positive and negative evidence and use judgments regarding past and future events,
including operating results and available tax planning strategies that could be implemented to realize the deferred tax assets. We record a valuation
allowance when necessary to reduce our deferred tax assets to the net amount that we believe is more likely than not to be realized. We consider available
evidence, both positive and negative, and use judgments regarding past and future events, including operating results and available tax planning strategies, in
assessing the need for a valuation allowance.
7
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 10
03/30/2018 02:52 PM
Significant judgment is required in determining income tax provisions and in evaluating tax positions. We establish additional provisions for income taxes
when, despite the belief that tax positions are fully supportable, there remain certain positions that do not meet the minimum probability threshold, which is a
tax position that is more likely than not to be sustained upon examination by the applicable taxing authority. In the normal course of business, we and our
subsidiaries are examined by various federal and state tax authorities. We regularly assess the potential outcomes of these examinations and any future
examinations for the current or prior years in determining the adequacy of our provision for income taxes. We adjust the income tax provision, the current
tax liability and deferred taxes in any period in which we become aware of facts that necessitate such an adjustment. The ultimate outcomes of the
examinations of our income tax returns could result in increases or decreases to our recorded tax liabilities, which would affect our financial results.
Intangible Assets
Intangible assets are acquired assets that lack physical substance and that meet specified criteria for recognition apart from goodwill. Our intangible assets
include trademarks, tradenames, patents and royalty rights. We own several trademarks and trade names, including Star brite® and Performacide®. We have
determined that these intangible assets have indefinite lives and, therefore, are not amortized. In addition, we own several patents, the most significant of
which are the ClO2 Patents, which relate to a device for producing chlorine dioxide that is incorporated in our deodorizer, sanitizer and disinfectant products.
We amortize our patents over their remaining life on a straight line basis; amortization expense related to the ClO2 patents was approximately $52,000
($51,000 for ClO2 patents and $1,000 for other patents) for each of the years ended December 31, 2017 and 2016. In 2013, we acquired royalty rights relating
to sales of products encompassing the ClO2 Patents’ technology (we purchased these rights from an unaffiliated entity that previously owned the ClO2
Patents and retained the royalty rights after selling the patents). We are amortizing the royalty rights over their remaining life on a straight line basis;
amortization expense relating to the royalty rights was approximately $18,000 for each of the years ended December 31, 2017 and 2016. See Note 7 to the
consolidated financial statements included in this report for additional information.
We evaluate our indefinite-lived intangible assets (trademarks and trade names) for impairment annually and at other times if events or changes in
circumstances indicate that an impairment may have occurred. In evaluating our indefinite-lived intangible assets for impairment, we assess qualitative
factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. If, after
completing the qualitative assessment, we determine it is more likely than not that the fair value of the indefinite-lived intangible asset is greater than its
carrying amount, the asset is not impaired. If we conclude it is more likely than not that the fair value of the indefinite-lived intangible assets is less than the
carrying value, we would then proceed to a quantitative impairment test, which consists of a comparison of the fair value of the intangible assets to their
carrying amounts. In 2017, we performed a qualitative assessment on all of our indefinite lived assets and determined, based on the assessment, that their fair
values were more likely than not higher than their carrying values.
We assess the remaining useful life and recoverability of intangible assets having finite lives (patents and royalty rights) whenever events or changes in
circumstances indicate the carrying value of an asset may not be recoverable. Such events or circumstances may include, for example, the occurrence of an
adverse change with respect to a product line that utilizes the intangible assets. Significant judgments in this area involve determining whether such an event
or circumstance has occurred. Any impairment loss, if indicated, equals the amount by which the carrying amount of the asset exceeds the estimated fair
value of the asset.
Results of Operations:
The following table provides a summary of our financial results for the years ended December 31, 2017 and 2016:
Net sales
Cost of goods sold
Gross profit
Advertising and promotion
Selling and administrative
Operating income
Interest income (expense), net
Provision for income taxes
Net income
2017
38,933,458
24,436,780
14,496,678
3,523,710
7,297,538
3,675,430
2,065
(1,073,961)
2,603,534
$
$
$
$
8
2016
36,205,444
22,331,761
13,873,683
3,117,164
7,660,377
3,096,142
(17,820)
(983,151)
2,095,171
For The Years Ended December 31,
Percent
Change
Percentage of Net Sales
2016
2017
7.5%
9.4%
4.5%
13.0%
(4.7)%
18.7%
(111.6)%
9.2%
24.3%
100.0%
62.8%
37.2%
9.1%
18.7%
9.4%
0.0%
2.8%
6.7%
100.0%
61.7%
38.3%
8.6%
21.2%
8.6%
0.0%
2.7%
5.8%
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 11
03/30/2018 02:52 PM
Net sales for the year ended December 31, 2017 increased by approximately $2,728,000 or 7.5%, as compared to the year ended December 31, 2016. The net
sales increase principally is attributable to sales of our marine products to two of our largest customers. In addition, we experienced sales growth generally
with respect to a wide range of customers, including mass merchandisers, large home improvement and marine/sports retail chains, and online retailers.
Cost of goods sold increased by approximately $2,105,000 or 9.4% in 2017, as compared to 2016. The increase in cost of goods sold is principally a result of
increased sales volume, higher raw material costs on our winterizing products and higher manufacturing costs.
Gross profit increased by approximately $623,000 or 4.5% during 2017, as compared to 2016. As a percentage of net sales, gross profit decreased to 37.2%
in 2017 from 38.3% in 2016. The increase in gross profit in 2017 is primarily attributable to increased sales volume. The decrease in gross profit as a
percentage of net sales during 2017 is principally a result of lower profit margins on sales of our winterizing products due to both lower sales prices and
higher raw material costs.
Advertising and promotion expense increased by approximately $407,000 or 13.0% during 2017, as compared to 2016. As a percentage of net sales,
advertising and promotion expense increased to 9.1% in 2017 compared to 8.6% in 2016. The increase in advertising and promotion expense is primarily a
result of increases in customer cooperative advertising allowances provided to select customers and other marketing expenses.
Selling and administrative expenses decreased by approximately $363,000 or 4.7%, during 2017, as compared to 2016. The decrease reflects the
conclusion of the Advertising Litigation in 2016. In 2016, legal fees and expenses related to the Advertising Litigation were approximately $1,146,000. This
decrease was partially offset by increased employee compensation expenses (including salaries, commissions and stock awards); bad debt expense of
approximately $199,000, of which approximately $188,000 resulted from a customer’s bankruptcy; and increased costs of computer programming and other
information technology services. As a percentage of net sales, selling and administrative expenses decreased to 18.7 % in 2017 from 21.2% in 2016.
Interest income, net for the year ended December 31, 2017 was approximately $2,000; for the year ended December 31, 2016, interest expense, net was
approximately $18,000. Interest income in 2017 was generated principally by an escrow account in which a portion of the funds relating to an industrial
development bond financing were deposited pending our utilization of such funds in connection with the Expansion Project. The interest income was offset
principally by interest under an earlier term loan that matured on July 6, 2017; we paid all remaining principal and interest on the maturity date. The term
loan also was the source of our primary interest obligation in 2016.
Provision for income taxes increased by approximately $91,000 for the year ended December 31, 2017, or 29.2% of our pretax income, compared to
approximately $983,000 in the year ended December 31, 2016, or 31.9% of our pretax income. The increase in our provision for income taxes, which
principally was due to the increase in our operating income, was offset in part by the benefit reflecting the reduction of our U.S. corporate income tax rate
from 34% to 21% under the Tax Cuts and Jobs Act. We revalued our net deferred tax liabilities to give effect to the reduction in the corporate income tax
rate, which resulted in an approximately $91,000 tax benefit. For additional information, see Note 8 to the consolidated financial statements included in this
report.
Liquidity and Capital Resources:
Our cash balance was approximately $2,418,000 at December 31, 2017 compared to approximately $4,070,000 at December 31, 2016.
The following table summarizes our cash flows for the years ended December 31, 2017 and 2016:
Net cash provided by operating activities
Net cash used in investing activities
Net cash provided by (used in) financing activities
Effect of exchange rate fluctuations on cash
Net (decrease) increase in cash
9
Years Ended
December 31,
$
$
2017
2,928,277
(8,023,092)
3,442,826
28
$
(1,651,961) $
2016
3,025,585
(443,892)
(978,503)
(1,160)
1,602,030
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 12
03/30/2018 02:52 PM
Net cash provided by operating activities for the year ended December 31, 2017 decreased by approximately $97,000 or 3.2%, as compared to the year ended
December 31, 2016. The comparative decrease is attributable to changes in working capital (excluding cash) of approximately $1,099,000 for the year ended
December 31, 2017 as compared to changes of approximately $344,000 during the year ended December 31, 2016. These changes were mostly offset by an
increase in net income of approximately $508,000 combined with an increase of noncash expenses of approximately $158,000 during the year ended
December 31, 2017 as compared to the year ended December 31, 2016.
Inventories, net were approximately $9,074,000 and $8,601,000 at December 31, 2017 and 2016, respectively, representing an increase of approximately
$473,000 or 5.5% in 2017. The 2017 increase in inventories reflects anticipated demand in the first quarter of 2018.
Net trade accounts receivable at December 31, 2017 aggregated approximately $4,964,000, an increase of approximately $32,000 or 0.7% compared to
approximately $4,932,000 in net trade accounts receivable outstanding at December 31, 2016. Receivables due from affiliated companies aggregated
approximately $1,584,000 at December 31, 2017, an increase of approximately $394,000, or 33.1% over receivables due from affiliated companies of
approximately $1,190,000 at December 31, 2016.
Net cash used in investing activities for the year ended December 31, 2017 increased by approximately $7,579,000, as compared to the year ended December
31, 2016. The increase is primarily attributable to expenditures related to the Expansion Project and the classification of unused cash proceeds of an industrial
development bond financing with respect to the Expansion Project as restricted cash. The classification results from a lease agreement that places limitations
on our use of cash we received from the industrial development bond financing. See “Overview” above and Note 6 to the consolidated financial statements
included in this report for additional information.
Net cash provided by financing activities for the year ended December 31, 2017 was approximately $3,400,000 compared to net cash used of approximately
$979,000 for the year ended December 31, 2016. During the year ended December 31, 2017, we received proceeds of $4,500,000 from the industrial
development bond financing relating to the Expansion Project and had lower payments on long term debt because a term loan that had been outstanding since
2011 matured on July 6, 2017, at which date we repaid all outstanding principal and interest. These increases to cash were partially offset by payments for
debt issuance costs.
See Notes 4 and 6 to the consolidated financial statements included in this report for information concerning our principal credit facilities, consisting of
Kinpak’s obligations relating to an industrial development bond financing, the payment of which we have guaranteed and a revolving line of credit. At
December 31, 2017 and 2016, we had outstanding balances of approximately $4,463,000 and $260,000, under Kinpak’s obligations relating to the industrial
development bond financing and a previously outstanding term loan respectively, and no borrowings under our current and previous revolving credit
facilities. The loan agreement pertaining to our revolving line of credit, as amended, contains various covenants, including financial covenants requiring a
minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the four most recently completed fiscal quarters minus the sum of Company’s
distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) current maturities of Company long-term debt (as
defined) as of the end of the most recent fiscal quarter plus scheduled interest expense incurred over the most recently completed four fiscal quarters) of 1.20
to 1, tested quarterly and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1 as of the end
of each fiscal quarter. The agreement relating to the revolving line of credit generally defines “long term debt” as “debt instruments with a maturity
principal due date of one year or more in length,” including, among other listed contractual debt instruments, “revolving lines of credit” and “capital leases
obligations.” Our guarantee of Kinpak’s obligations related to the industrial development bond financing effectively is subject to substantially the same
financial covenants. For the year ended December 31, 2017, the Company’s fixed charge coverage ratio was approximately 7.30 to 1.00, and at December 31,
2017, the Company’s debt to capitalization ratio was approximately 0.15 to 1.00.
In addition to the industrial revenue bond financing and the revolving line of credit, we have obtained financing through capital leases for office equipment,
totaling approximately $50,000 and $69,000 at December 31, 2017 and 2016, respectively.
Some of our assets and liabilities are denominated in Canadian dollars and are subject to currency exchange rate fluctuations. We do not engage in currency
hedging and address currency risk as a pricing issue. For the year ended December 31, 2017, we recorded $1,496 in foreign currency translation adjustments
(decreasing shareholders’ equity by $1,496).
During the past few years, we have introduced a number of new products. At times, new product introductions have required us to increase our overall
inventory and have resulted in lower inventory turnover rates. The effects of reduced inventory turnover have not been material to our overall
operations. We believe that all capital required to fund any inventory increases will continue to be provided by operations and, if necessary, our current
revolving line of credit or a renewal or replacement of the facility. However, we cannot assure that we will be able to secure such a renewal or replacement
of our revolving line of credit.
Many of the raw materials that we use in the manufacturing process are petroleum or chemical based and commodity chemicals that are subject to fluctuating
prices. The nature of our business does not enable us to pass through the price increases to our national retailer customers and to our distributors as promptly
as we experience increases in raw material costs. This may, at times, adversely affect our margins.
As noted above, we are in the final stages of the Expansion Project, which entails an approximately 85,000 square feet addition to Kinpak’s manufacturing
facilities and an expansion of Kinpak’s outdoor tank farm to accommodate an additional 500,000 gallons in tank capacity. The addition to the facilities and
expansion of the tank farm are completed. The remaining parts of the Expansion Project involve additional upgrades to the warehouse facilities and the
installation of new manufacturing equipment. At December 31, 2017, expenditures in connection with the Expansion Project aggregated approximately $5.1
million, and we estimate that the total cost of the Expansion Project will be approximately $6.0 million. The Expansion Project is expected to be completed
and placed into service during 2018. The Expansion Project is being financed primarily with the proceeds of the industrial development bond financing,
which is described in Note 6 to the consolidated financial statements included in this report. The Expansion Project also is being funded with cash from
operations.
10
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 13
03/30/2018 02:52 PM
We believe that funds provided through operations and other sources of financing will be sufficient to satisfy our cash requirements over at least the next
twelve months.
Item 7A. Quantitative and Qualitative Disclosure about Market Risk
Not applicable.
Item 8. Financial Statements and Supplementary Data
The audited financial statements of the Company required pursuant to this Item 8 are included in a separate section commencing on page F-1 and are
incorporated herein by reference.
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A. Controls and Procedures:
Evaluation of Disclosure Controls and Procedures. The Company’s management, with the participation of the Company’s Chief Executive Officer and
Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under
the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) at the end of the period covered by this report. Based on that evaluation, the Chief
Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, the Company’s disclosure controls and
procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act
are (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii)
accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow
timely decisions regarding required disclosure.
Change in Internal Controls over Financial Reporting. No change in internal control over financial reporting (as defined in Rule 13a-15(f) under the
Exchange Act) occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
Company’s internal control over financial reporting.
Management’s Annual Report on Internal Control over Financial Reporting
Management of Ocean Bio-Chem, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes
those policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in
accordance with authorizations of management and directors of the company; and provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
Management evaluated the Company’s internal control over financial reporting as of December 31, 2017. In making this assessment, management used the
framework established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO). As a result of this assessment and based on the criteria in the COSO framework, management has concluded that, as of December 31,
2017, the Company’s internal control over financial reporting was effective.
Item 9B. Other Information
Not applicable.
11
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 14
03/30/2018 02:52 PM
Item 10. Directors, Executive Officers and Corporate Governance
PART III
Information required by this item is incorporated by reference to the Company’s definitive proxy statement, which will be filed with the Commission no later
than 120 days after the close of the fiscal year covered by this report.
Item 11. Executive Compensation
Information required by this item is incorporated by reference to the Company’s definitive proxy statement, which will be filed with the Commission no later
than 120 days after the close of the fiscal year covered by this report.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Information required by this item is incorporated by reference to the Company’s definitive proxy statement, which will be filed with the Commission no later
than 120 days after the close of the fiscal year covered by this report.
Item 13. Certain Relationships and Related Transactions, and Director Independence
Information required by this item is incorporated by reference to the Company’s definitive proxy statement, which will be filed with the Commission no later
than 120 days after the close of the fiscal year covered by this report.
Item 14. Principal Accounting Fees and Services
Information required by this item is incorporated by reference to the Company’s definitive proxy statement, which will be filed with the Commission no later
than 120 days after the close of the fiscal year covered by this report.
12
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 15
03/30/2018 02:52 PM
PART IV
Item 15. Exhibits, Financial Statement Schedules
(a)
(b)
Financial Statements – See the Index to Consolidated Financial Statements on page F-1.
Exhibits:
Unless otherwise noted, the file number of each referenced filing is 0-11102.
Exhibit No.
3.1.1
3.1.2
3.2
10.1.1
10.1.2
10.1.3
*10.1.4
†10.2
10.3.1
10.3.2
10.3.3
10.3.4
†10.4
†10.5
10.6.1
10.6.2
10.6.3
*21
*23
*31.1
*31.2
*32.1
*32.2
101
Articles of Incorporation and amendments through May 20, 1994 (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on
Form 10-K for the year ended December 31, 2010).
Articles of Amendment to the Articles of Incorporation, as filed on June 13, 2012 (incorporated by reference to Exhibit 3.1.2 to the Company's
Annual Report on Form 10-K for the year ended December 31, 2012).
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the
Securities and Exchange Commission on December 5, 2011).
Business Loan Agreement, dated August 31, 2017, between the Company and Regions Bank (the “Business Loan Agreement”) (incorporated
by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017).
Promissory Note, dated August 31, 2017, issued by the Company to Regions Bank in connection with the revolving line of credit under the
Business Loan Agreement (the “Promissory Note”) (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form
10-Q for the quarter ended September 30, 2017).
Letter, dated August 31, 2017, from Regions Bank to the Company, regarding certain terms under the Business Loan Agreement and the
Promissory Note (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September
30, 2017).
Letter, dated December 20, 2017, from Regions Bank to the Company, regarding certain terms of the Business Loan Agreement.
Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan, as amended (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly
Report on Form 10-Q, filed with the Securities and Exchange Commission on August 12, 2016).
Form of Industrial Development Revenue Bond (Kinpak Inc. Project) Series 2017 (incorporated by reference to Exhibit 99.1 to the Company’s
Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 2, 2017).
Second Restated Lease Agreement, dated as of September 1, 2017, between The Industrial Development Board of the City of Montgomery and
KINPAK, Inc. (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K, filed with the Securities and
Exchange Commission on October 2, 2017).
Mortgage, Security Agreement and Assignment of Rents and Leases, dated as of September 1, 2017, provided by The Industrial Development
Board of the City of Montgomery and KINPAK, Inc. (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K,
filed with the Securities and Exchange Commission on October 2, 2017).
Guaranty Agreement, dated as of September 1, 2017, provided by Ocean Bio-Chem, Inc. and its consolidated subsidiaries party
thereto (incorporated by reference to Exhibit 99.4 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange
Commission on October 2, 2017).
Ocean Bio-Chem, Inc. 2002 Non-Qualified Stock Option Plan, as amended (incorporated by reference to Exhibit 99.2 to the Company’s
Registration Statement on Form S-8 (File No. 333-176268), filed with the Securities and Exchange Commission on August 12, 2011).
Ocean Bio-Chem, Inc. 2008 Non-Qualified Stock Option Plan, as amended (incorporated by reference to Exhibit 99.5 to the Company’s
Registration Statement on Form S-8 (File No. 333-176268), filed with the Securities and Exchange Commission on August 12, 2011).
Net Lease, dated May 1, 1998, between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to Exhibit 10.14 to the
Company’s Annual Report on Form 10-K for the year ended December 31, 2004).
Renewal of Lease, dated May 1, 2008, between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to Exhibit 10.24 to the
Company’s Annual Report on Form 10-K for the year ended December 31, 2008).
Amendment Number Two to Net Lease, dated May 16, 2013, between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to
Exhibit 10.13 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013).
List of Subsidiaries
Consent of EisnerAmper LLP
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act and 18 U.S.C. Section 1350.
Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act and 18 U.S.C. Section 1350.
The following materials from Ocean Bio-Chem Inc.’s Annual Report on Form 10-K for the year ended December 31, 2017, formatted in XBLR
(eXtensible Business Reporting Language): (i) Consolidated Balance Sheets at December 31, 2017 and December 31, 2016; (ii) Consolidated
Statements of Operations for the years ended December 31, 2017 and 2016; (iii) Consolidated Statements of Comprehensive Income for the
years ended December 31, 2017 and 2016; (iv) Consolidated Statements of Changes in Shareholders Equity for the years ended December 31,
2017 and 2016, (v) Consolidated Statements of Cash Flows for the years ended December 31, 2017 and 2016 and (vi) Notes to Consolidated
Financial Statements.
*
†
Filed herewith.
Constitutes management contract or compensatory plan or arrangement required to be filed as in exhibit to this report.
Item 16. Form 10-K Summary
Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include a
summary
13
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 16
03/30/2018 02:52 PM
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Date: March 30, 2018
OCEAN BIO-CHEM, INC.
By:
/s/ Peter G. Dornau
PETER G. DORNAU
Chairman of the Board, President and
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in
the capacities and on the dates indicated.
Signature
Capacity
/s/ Peter G. Dornau
Peter G. Dornau
/s/ Jeffrey S. Barocas
Jeffrey S. Barocas
/s/ Diana Mazuelos Conard
Diana Mazuelos Conard
/s/ Gregor M. Dornau
Gregor M. Dornau
/s/ William W. Dudman
William W. Dudman
/s/ James M. Kolisch
James M. Kolisch
/s/ Kimberly A. Krause
Kimberly A. Krause
/s/ John B. Turner
John B. Turner
Chairman of the Board, President and
Chief Executive Officer
(Principal Executive Officer)
Vice President, Chief Financial Officer
(Principal Financial and Accounting Officer)
Director
Director
Director
Director
Director
Director
14
Date
March 30, 2018
March 30, 2018
March 30, 2018
March 30, 2018
March 30, 2018
March 30, 2018
March 30, 2018
March 30, 2018
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 17
03/30/2018 02:52 PM
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Report of independent registered public accounting firm
Consolidated balance sheets
Consolidated statements of operations
Consolidated statements of comprehensive income
Consolidated statements of shareholders’ equity
Consolidated statements of cash flows
Notes to consolidated financial statements
F-1
Page
F-2
F-3
F-4
F-5
F-6
F-7
F-8 - F-17
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 18
03/30/2018 02:52 PM
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Shareholders of
Ocean Bio Chem, Inc. and Subsidiaries
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Ocean Bio-Chem, Inc. and Subsidiaries (the “Company") as of December 31, 2017 and
2016 and the related consolidated statements of operations, comprehensive income, shareholders’ equity, and cash flows for each of the years then ended, and
the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the
consolidated financial position of the Company as of December 31, 2017 and 2016 and the consolidated results of their operations and their cash flows for
each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of
internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial
reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in
the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ EisnerAmper LLP
We have served as the Company’s auditor since 2017.
EISNERAMPER LLP
Fort Lauderdale, Florida
March 30, 2018
F-2
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 19
03/30/2018 02:52 PM
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2017 AND 2016
ASSETS
Current Assets:
Cash
Trade accounts receivable less allowances of approximately $79,000 and $75,000, respectively
Receivables due from affiliated companies
Restricted cash
Inventories, net
Prepaid expenses and other current assets
Total Current Assets
Property, plant and equipment, net
Intangible assets, net
Total Assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Current portion of long-term debt, net
Accounts payable - trade
Income taxes payable
Accrued expenses payable
Total Current Liabilities
Deferred tax liability
Long-term debt, less current portion and debt issuance costs
Total Liabilities
Commitments and contingencies
Shareholders’ Equity:
Common stock - $.01 par value, 12,000,000 shares authorized; 9,254,580 shares and 9,146,937 shares issued,
respectively
Additional paid in capital
Accumulated other comprehensive loss
Retained earnings
Total Shareholders’ Equity
Total Liabilities and Shareholders’ Equity
The accompanying notes are an integral part of these consolidated financial statements.
F-3
2017
2016
$
$
$
$
$
$
2,418,484
4,963,895
1,584,365
2,747,360
9,074,426
1,013,213
21,801,743
9,291,667
897,408
31,990,818
240,017
1,807,120
---
812,062
2,859,199
153,895
4,081,793
7,094,887
4,070,445
4,931,792
1,190,103
---
8,600,689
1,013,952
19,806,981
4,895,973
967,688
25,670,642
278,392
1,512,020
1,447
1,099,919
2,891,778
213,367
50,426
3,155,571
92,546
9,931,634
(288,051)
15,159,802
24,895,931
91,469
9,604,634
(286,555)
13,105,523
22,515,071
$
31,990,818
$
25,670,642
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 20
03/30/2018 02:52 PM
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2017 AND 2016
Net sales
Cost of goods sold
Gross profit
Operating Expenses:
Advertising and promotion
Selling and administrative
Total operating expenses
Operating income
Other income (expense)
Interest net, income (expense)
Income before income taxes
Provision for income taxes
Net income
Earnings per common share – basic and diluted
Dividends declared per common share
The accompanying notes are an integral part of these consolidated financial statements.
F-4
2017
2016
$
38,933,458
$
36,205,444
24,436,780
22,331,761
14,496,678
13,873,683
3,523,710
7,297,538
10,821,248
3,117,164
7,660,377
10,777,541
3,675,430
3,096,142
2,065
(17,820)
3,677,495
3,078,322
(1,073,961)
(983,151)
$
$
$
2,603,534
0.28
0.06
$
$
$
2,095,171
0.23
0.06
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 21
03/30/2018 02:52 PM
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2017 AND 2016
Net income
Foreign currency translation adjustment
Comprehensive income
The accompanying notes are an integral part of these consolidated financial statements.
F-5
2017
2016
$
2,603,534
$
2,095,171
(1,496)
(2,113)
$
2,602,038
$
2,093,058
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 22
03/30/2018 02:52 PM
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
YEARS ENDED DECEMBER 31, 2017 AND 2016
Common Stock
Shares
Amount
Additional
Paid In
Capital
Accumulated
Other
Comprehensive
loss
Retained
Earnings
Total
8,983,374
$
89,834
$
9,287,313
$
(284,442) $
11,550,883
$
20,643,588
January 1, 2016
Net income
Dividends declared and paid
Options exercised
25,481
255
21,345
Common stock issued, net of shares
withheld for employee taxes
Foreign currency
translation adjustment
138,082
1,380
295,976
2,095,171
2,095,171
(540,531)
(540,531)
21,600
297,356
(2,113)
(2,113)
December 31, 2016
9,146,937
$
91,469
$
9,604,634
$
(286,555) $
13,105,523
$
22,515,071
Net income
Dividends declared and paid
Options exercised
Common stock issued, net of shares
withheld for employee taxes
Foreign currency translation adjustment
34,043
73,600
341
736
26,059
300,941
2,603,534
2,603,534
(549,255)
(549,255)
26,400
301,677
(1,496)
(1,496)
December 31, 2017
9,254,580
$
92,546
$
9,931,634
$
(288,051) $
15,159,802
$
24,895,931
The accompanying notes are an integral part of these consolidated financial statements.
F-6
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 23
03/30/2018 02:52 PM
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2017 AND 2016
Cash flows from operating activities:
Net income
Adjustment to reconcile net income to net cash provided by operations:
Depreciation and amortization
Deferred income taxes
Stock based compensation
Provision for bad debts
Other operating noncash items
Changes in assets and liabilities:
Trade accounts receivable
Receivables due from affiliated companies
Inventories
Prepaid expenses and other current assets
Accounts payable
Income taxes payable
Accrued expenses payable
Net cash provided by operating activities
Cash flows from investing activities:
Purchases of property, plant and equipment
Increase in cash restricted for plant expansion
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from long term debt
Payments on long-term debt
Borrowings on revolving line of credit
Repayments on revolving line of credit
Payments for taxes related to net share settlements of stock awards
Dividends paid to common shareholders
Payments for debt issuance costs
Proceeds from exercise of stock options
Net cash provided by (used in) financing activities
Effect of exchange rate on cash
Net (decrease) increase in cash
Cash at beginning of the year
Cash at end of the year
Supplemental disclosure of cash transactions:
Cash paid for interest during the year
Cash paid for income taxes during the year
The accompanying notes are an integral part of these consolidated financial statements.
F-7
2017
2016
$
2,603,534
$
2,095,171
955,161
(59,472)
324,145
198,839
4,612
(230,942)
(394,262)
(479,873)
739
295,100
(1,447)
(287,857)
2,928,277
(5,275,732)
(2,747,360)
(8,023,092)
4,500,000
(315,756)
1,000,000
(1,000,000)
(22,468)
(549,255)
(196,095)
26,400
3,442,826
28
(1,651,961)
4,070,445
2,418,484
29,496
1,282,400
$
$
$
974,587
(26,310)
305,780
(3,272)
14,044
163,520
(139,012)
(700,736)
(71,132)
410,300
1,447
1,198
3,025,585
(443,892)
---
(443,892)
---
(451,148)
---
---
(8,424)
(540,531)
---
21,600
(978,503)
(1,160)
1,602,030
2,468,415
4,070,445
19,096
993,600
$
$
$
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 24
03/30/2018 02:52 PM
OCEAN BIO-CHEM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2017 AND 2016
Note 1 – Organization and summary of significant accounting policies:
Organization – The Company was incorporated in November 1973 under the laws of the state of Florida and manufacturers, markets and distributes products,
principally under the Star brite® and Star Tron® brand names, for the marine, automotive, power sports, recreational vehicle and outdoor power equipment
markets in the United States and Canada. In addition, the Company produces private label formulations of many of its products for various customers and
provides custom blending and packaging services for these and other products. The Company also manufactures disinfectants, sanitizers and deodorizers
under the Performacide® and Star brite® brand names.
Basis of presentation – The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-
company accounts and transactions have been eliminated in consolidation. Certain prior-period data have been reclassified to conform to the current period
presentation.
Revenue recognition – Revenue from product sales is recognized when persuasive evidence of a contract exists, the sales price is fixed and determinable, the
title of goods passes to the customer, and collectability of the related receivable is probable. Reported net sales are net of customer prompt pay discounts,
contractual allowances, authorized customer returns, consumer rebates and other sales incentives.
Collectability of accounts receivable – Trade accounts receivable at December 31, 2017 and 2016 are net of allowances for doubtful accounts aggregating
approximately $79,000 and $75,000, respectively. Such amounts are based on expected collectability of the trade accounts receivable, after considering the
Company’s historical collection experience, the length of time an account is outstanding, the financial position of the customer if known and information
provided by credit rating services. During the year ended December 31, 2017, the Company recorded bad debt expense of approximately $199,000. During
the year ended December 31, 2016, the Company reduced its bad debt reserve by approximately $3,000, resulting in an increase to net income.
Inventories – Inventories are primarily composed of raw materials and finished goods and are stated at the lower of cost, using the first-in, first-out method,
or market.
Shipping and handling costs – All shipping and handling costs incurred by the Company are included in cost of goods sold in the consolidated statements of
operations. Shipping and handling costs totaled approximately $1,226,000 and $1,120,000 for the years ended December 31, 2017 and 2016, respectively.
Advertising and promotion expense – Advertising and promotion expense consists of advertising costs and marketing expenses, including catalog costs and
expenses relating to participation at trade shows. Advertising costs are expensed in the period in which the advertising occurs and totaled approximately
$3,524,000 and $3,117,000 in 2017 and 2016, respectively.
Property, plant and equipment – Property, plant and equipment is stated at cost, net of depreciation. Depreciation is provided over the estimated useful lives
of the related assets using the straight-line method. Depreciation expense totaled $884,881 and $904,307 for the years ended December 31, 2017 and 2016,
respectively.
Research and development costs – Research and development costs are expensed as incurred and recorded in selling and administrative expenses in the
consolidated statements of operations. The Company incurred approximately $42,000 and $46,000 of research and development costs for the years ended
December 31, 2017 and 2016, respectively.
Stock based compensation – The Company records stock-based compensation in accordance with the provisions of Financial Accounting Standards Board
(“FASB”) Accounting Standards Codification (“ASC") Topic 718, "Accounting for Stock Compensation," which establishes accounting standards for
transactions in which an entity exchanges its equity instruments for goods or services. In accordance with guidance provided under ASC Topic 718, we
recognize an expense for the fair value of our stock awards at the time of grant and the fair value of our outstanding stock options as they vest, whether held
by employees or others. As of December 31, 2017, all outstanding stock options were vested.
Use of estimates – The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
F-8
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 25
03/30/2018 02:52 PM
Concentration of cash – At various times during the years ended and at December 31, 2017 and 2016, the Company had a concentration of cash in one bank
in excess of prevailing insurance offered through the Federal Deposit Insurance Corporation at such institution. Management does not consider the excess
deposits to be a significant risk.
Fair value of financial instruments – ASC Topic 820, “Fair Value Measurements and Disclosures” defines “fair value” as the price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date.
ASC Topic 820 also sets forth a valuation hierarchy of the inputs (assumptions that market participants would use in pricing an asset or liability) used to
measure fair value. The hierarchy prioritizes the three levels of inputs as follows:
Level 1: Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities traded in active markets.
Level 2: Inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in
markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or
corroborated by observable market data through correlation or other means.
Level 3: Inputs that are generally unobservable. These inputs may be used with internally developed methodologies that result in management’s best
estimate of fair value.
The carrying amounts of the Company’s short-term financial instruments, including cash, accounts receivable, accounts payable, certain accrued expenses
and revolving line of credit, approximate their fair value due to the relatively short period to maturity for these instruments. The fair value of long-term debt
is based on current rates at which the Company could borrow funds with similar remaining maturities; the carrying amount of the long-term debt
approximates fair value.
Impairment of long-lived assets – Potential impairments of long-lived assets are reviewed when events or changes in circumstances indicate a potential
impairment may exist. In accordance with ASC Subtopic 360-10, “Property, Plant and Equipment – Overall,” impairment is determined when estimated
future undiscounted cash flows associated with an asset are less than the asset’s carrying value.
Income taxes – The Company records income taxes under the asset and liability method. Under this method, the Company recognizes deferred income tax
assets and liabilities for the expected future consequences attributable to temporary differences between the financial reporting and tax bases of assets and
liabilities. These differences are measured using tax rates that are expected to apply to taxable income in the years in which those temporary differences are
recovered or settled. We recognize in the statement of operations the effect on deferred income taxes of a change in tax rates in the period in which the
change is enacted.
We record a valuation allowance when necessary to reduce our deferred tax assets to the net amount that we believe is more likely than not to be realized. We
consider available evidence, both positive and negative, and use judgments regarding past and future events, including operating results and available tax
planning strategies, in assessing the need for a valuation allowance.
We recognize tax benefits from uncertain tax positions only if we believe that it is more likely than not that the tax positions will be sustained on examination
by the taxing authorities based on the technical merits of the positions; otherwise, we establish reserves for uncertain tax positions. We adjust reserves with
respect to uncertain tax positions to address developments related to these positions, such as the closing of a tax audit, the expiration of a statute of limitations
or the refinement of an estimate. The provision for income taxes includes any reserves with respect to uncertain tax positions that are considered appropriate,
as well as the related net interest and penalties. The Company has no uncertain tax positions as of December 31, 2017.
The Company is no longer subject to income tax examinations for years before 2014.
Intangible assets – The Company’s intangible assets consist of trademarks, trade names, patents and royalty rights. The Company evaluates trademarks and
trade names (all of which are indefinite-lived intangible assets) for impairment at least annually or when events or changes in circumstances indicate a
potential impairment may exist. The Company evaluates royalty rights and patents (which are amortized on a straight-line basis over their useful lives) for
impairment when events or changes in circumstances indicate an impairment may exist. No impairment was recorded in 2017 or 2016.
Foreign currency translation – Assets and liabilities of the Company’s Canadian subsidiary are translated from Canadian dollars to United States dollars at
exchange rates in effect at the balance sheet date. Income and expenses are translated at average exchange rates during the year. The translation adjustments
for the reporting period are included in our statements of comprehensive income, and the cumulative effect of these adjustments are reported in the
Company’s balance sheet as accumulated other comprehensive loss within Shareholders’ Equity.
Earnings per share – Basic earnings per share are computed by dividing net earnings available to common shareholders by the weighted average number of
common shares outstanding during the period. Diluted earnings per share are computed assuming the exercise of dilutive stock options under the treasury
stock method and the related income tax effects. See Note 14 - Earnings per share.
F-9
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 26
03/30/2018 02:52 PM
Note 2 – Inventories:
The composition of inventories at December 31, 2017 and 2016 are as follows:
Raw materials
Finished goods
Inventories, gross
Inventory reserves
Inventories, net
$
2017
3,994,624
5,354,097
9,348,721
$
2016
3,633,641
5,235,207
8,868,848
(274,295)
(268,159)
$
9,074,426
$
8,600,689
The inventory reserves shown in the table above reflect slow moving and obsolete inventory.
The Company operates a vendor managed inventory program with one of its customers to improve the promotion of the Company’s products. The Company
manages the inventory levels at this customer’s warehouses and recognizes revenue as the products are sold by the customer. The inventories managed at the
customer’s warehouses, which are included in inventories, net, amounted to approximately $494,000 and $551,000 at December 31, 2017 and 2016,
respectively.
Note 3 – Property, plant and equipment:
The Company’s property, plant and equipment at December 31, 2017 and 2016 consisted of the following:
Land
Building and Improvements
Manufacturing and warehouse equipment
Office equipment and furniture
Leasehold improvements
Vehicles
Construction in process
Property, plant and equipment, gross
Less accumulated depreciation
Property, plant and equipment, net
Estimated
Useful Life
30 years
6-20 years
3-5 years
10-15 years
3 years
2017
2016
$
$
278,325
4,673,409
9,616,086
1,367,244
567,898
10,020
5,197,780
21,710,762
278,325
4,652,669
9,239,876
1,344,732
558,666
10,020
387,417
16,471,705
(12,419,095)
(11,575,732)
$
9,291,667
$
4,895,973
Construction in progress at December 31, 2017 and 2016 includes $5,087,897 and $188,041, respectively, relating to the expansion of the manufacturing,
warehouse and distribution facilities of the Company’s wholly-owned subsidiary, KINPAK Inc. (“Kinpak”), in Montgomery, Alabama. The Company
estimates that the total cost of this expansion project will be approximately $6.0 million, and the project is expected to be completed and placed into service
during 2018.
Note 4 – Revolving line of credit:
On August 31, 2017, the Company and Regions Bank entered into a Business Loan Agreement (the “Business Loan Agreement”), under which the Company
was provided a revolving line of credit. Under the Business Loan Agreement, the Company may borrow up to the lesser of (i) $6,000,000 or (ii) a borrowing
base equal to 85% of Eligible Accounts (as defined in the Business Loan Agreement) plus 50% of Eligible Inventory (as defined in the Business Loan
Agreement). Interest on amounts borrowed under the revolving line of credit is payable monthly at the one month LIBOR rate plus 1.5% per annum,
computed on a 365/360 basis. Eligible Accounts do not include, among other things, accounts receivable from affiliated entities.
Outstanding amounts under the revolving line of credit are payable on demand. If no demand is made, the Company may repay and reborrow funds from
time to time until expiration of the revolving line of credit on August 31, 2018, at which time all outstanding principal and interest will be due and payable.
The Company’s obligations under the revolving line of credit are secured by, among other things, the Company’s accounts receivable and inventory. The
Business Loan Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of
(A) EBITDA for the most recently completed four fiscal quarters minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded
capital expenditures during such period to (B) current maturities of Company long term debt as of the end of the most recent fiscal quarter plus scheduled
interest expense incurred over the most recently completed four fiscal quarters) of 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally,
funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter. For purposes of computing the fixed charge
coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus
non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures’ generally is
defined as ‘capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures; and
‘long term debt’ generally is defined as “debt instruments with a maturity principal due date of one year or more in length,” including, among other listed
contractual debt instruments, “revolving lines of credit” and “capital leases obligations.” For the year ended December 31, 2017, the Company’s fixed charge
coverage ratio was approximately 7.30 to 1.00, and at December 31, 2017, the Company’s debt to capitalization ratio was approximately 0.15 to 1.00. The
revolving line of credit is subject to several events of default, including a decline in the majority shareholder’s ownership below 50% of all outstanding
shares. At December 31, 2017 and 2016, the Company had no borrowings under its revolving line of credit in connection with the Business Loan Agreement
and a predecessor agreement previously in effect.
F-10
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 27
03/30/2018 02:52 PM
Note 5 – Accrued expenses payable:
Accrued expenses payable at December 31, 2017 and 2016 consisted of the following:
Accrued customer promotions
Accrued payroll, commissions, and benefits
Other
Total accrued expenses payable
Note 6 – Long-term debt:
Industrial Development Bond Financing
2017
2016
$
$
$
343,172
280,783
188,107
546,127
287,376
266,416
812,062
$
1,099,919
On September 26, 2017, the Company’s wholly-owned subsidiary, KINPAK, Inc. (“Kinpak”) indirectly obtained a $4,500,000 loan from Regions Capital
Advantage, Inc. (the “Lender”). The proceeds of the loan are being used principally to pay or reimburse costs of constructing an approximately 85,000 square
foot addition to Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama, and costs of purchasing and installing associated
machinery and equipment (the “Project”).
The loan was funded by the Lender’s purchase of a $4,500,000 industrial development bond (the “Bond”) issued by The Industrial Development Board of the
City of Montgomery, Alabama (the “IDB”). The Bond is a limited obligation of the IDB and is payable solely out of revenues and receipts derived from the
leasing or sale of Kinpak’s facilities. In this regard, Kinpak is obligated to fund the IDB’s payment obligations by providing rental payments under a lease
between the IDB and Kinpak (the “Lease”), under which Kinpak leases its facilities from the IDB. Under the Lease, prior to the maturity date of the Bond,
Kinpak may repurchase the facilities for $1,000 if the Bond has been redeemed or fully paid.
The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase
to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and
ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027 in the amount of $1,799,201. The Bond provides that
the interest rate will be subject to adjustment if it is determined by the United States Treasury Department, the Internal Revenue Service, or a similar
government entity that the interest on the Bond is includable in the gross income of the Lender for federal income tax purposes.
Under the Lease, Kinpak is required to make rental payments for the account of the IDB to the Lender in such amounts and at such times as are necessary to
enable the payment of all principal and interest due on the Bond and other charges, if any, payable in respect of the Bond. The Lease also provides that
Kinpak may redeem the Bond, in whole or in part, by prepaying its rental payment obligations in an amount sufficient to effect the redemption. In addition,
the Lease contains provisions relating to the Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial
account (as described below) and investment of monies held in the custodial account.
Payment of amounts due and payable under the Bond and other related agreements are guaranteed by the Company and its other consolidated subsidiaries. In
connection with its guarantee, the Company is subject to certain covenants, including financial covenants that effectively are substantially the same as the
financial covenants included in the Business Loan Agreement described in Note 4.
Through December 31, 2017, of the $4,500,000 proceeds of the Bond sale, approximately $1,699,000 has been applied to reimburse Kinpak for Project
expenditures and approximately $54,000 was paid directly to other parties for certain transaction costs. The remaining amount is deposited into a custodial
account and will be drawn by Kinpak from time to time to fund additional expenditures related to the Project. Because the Lease contains limitations on the
manner in which the Kinpak may utilize funds held in the custodial account, such funds are classified as restricted cash on the Company’s balance sheet.
The Company incurred debt financing costs of $196,095 in connection with the financing. These costs are shown as a reduction of the debt balance and are
being amortized under the effective interest method.
F-11
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 28
03/30/2018 02:52 PM
Other Long Term Obligations
On July 6, 2011, in connection with a credit agreement among the Company, Kinpak, Regions Bank and Regions Equipment Finance Corporation
(“REFCO”), an Equipment Finance Addendum to a previously outstanding credit agreement (the “Addendum”) was entered into by the Company, Kinpak
and REFCO. Under the Addendum, REFCO provided to the Company a $2,430,000 term loan with a fixed interest rate of 3.54% per annum. The proceeds
of the term loan were used to pay Kinpak’s remaining obligations under a lease agreement relating to industrial revenue bonds used to fund a previous
expansion of Kinpak’s facilities and acquisition of related equipment. The term loan matured on July 6, 2017, and the Company paid all remaining principal
and interest at maturity.
At December 31, 2017 and 2016, the Company was obligated under capital lease agreements covering equipment utilized in the Company’s operations. The
capital leases, aggregating approximately $50,000 and $69,000 at December 31, 2017 and 2016, respectively, mature on July 1, 2020 and carry an interest
rate of 2%.
The following table provides information regarding the Company’s long-term debt at December 31, 2017 and 2016:
Current Portion
Long Term Portion
$
December 31,
2017
4,222,241
---
31,188
4,253,429
(171,636)
4,081,793
$
Obligations related to industrial development bond financing
Term loan
Capitalized equipment leases
Total principal of long term debt
Debt issuance costs
Total long term debt
December 31,
2017
December 31,
2016
$
$
240,395
---
19,238
259,633
(19,616)
240,017
$
$
---
259,503
18,889
278,392
---
278,392
Required principal payments under the Company’s term loan and capital lease obligations are set forth below:
Year ending December 31,
2018
2019
2020
2021
2022
Thereafter
Total
Note 7 – Intangible Assets:
The Company’s intangible assets at December 31, 2017 and 2016 consisted of the following:
December 31, 2017
Intangible Assets
Patents
Trade names and trademarks
Royalty rights
Total intangible assets
December 31, 2016
Intangible Assets
Patents
Trade names and trademarks
Royalty rights
Total intangible assets
$
$
$
$
F-12
Cost
622,733
1,131,125
160,000
1,913,858
Accumulated
Amortization
$
387,636
549,561
79,253
1.016,450
$
Cost
622,733
1,131,125
160,000
1,913,858
$
$
Accumulated
Amortization
335,300
549,561
61,309
946,170
December 31,
2016
$
$
$
$
$
$
$
$
---
---
50,426
50,426
---
50,426
259,633
267,578
267,066
263,881
272,213
3,182,691
4,513,062
Net
235,097
581,564
80,747
897,408
Net
287,433
581,564
98,691
967,688
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 29
03/30/2018 02:52 PM
At December 31, 2017 and 2016, the trade names and trademarks are considered indefinite-lived. The patents (the most significant of which (the “ClO2
Patents”) relate to a device for producing chlorine dioxide (ClO2) that is incorporated into the Company’s disinfectant, sanitizer and deodorizer products) had
a carrying value, net of amortization, of $235,097 at December 31, 2017 (of which $231,515 is attributable to the ClO2 Patents). The ClO2 Patents expire in
2022 and the other patents expire in 2021. The royalty rights (which the Company purchased from an unaffiliated entity that previously owned the ClO2
Patents and retained the royalty rights after selling the patents) expire in December 2021 and are amortized on a straight line basis over their remaining useful
lives.
Amortization expense related to intangible assets was $70,280 ($52,336 attributable to the patents and $17,944 attributable to the royalty rights) for each of
the years ended December 31, 2017 and 2016.
Note 8 – Income taxes:
The components of the Company’s consolidated provision (benefit) for income taxes are as follows:
Federal – current
Federal – deferred
State – current
State – deferred
Total provision for income taxes
2017
1,101,503
(60,364)
31,930
892
1,073,961
$
$
2016
982,298
(25,565)
27,163
(745)
983,151
$
$
The reconciliation of the provision for income taxes at the statutory rate to the reported provision for income taxes is as follows:
Income Tax computed at statutory rate
State tax, net of federal benefit
Share based compensation
Domestic production activities deduction
Effect of tax rate change on deferred taxes
Permanent adjustments
Tax credits and other
Provision for income taxes
2017
1,250,348
21,074
(6,303)
(110,410)
(90,980)
24,202
(13,970)
1,073,961
$
$
%
34.0% $
0.6%
(0.2)%
(3.0)%
(2.5)%
0.7%
(0.4)%
29.2% $
2016
1,046,629
17,916
(2,013)
(97,645)
---
23,991
(5,727)
983,151
%
34.0%
0.6%
(0.1)%
(3.2)%
0.0%
0.8%
(0.2)%
31.9%
The Company’s deferred tax asset (liability) consisted of the following at December 31, 2017 and 2016:
Deferred tax asset (liability)
Inventory reserves
Trade accounts receivable allowances
Net Operating loss carryforward state
Depreciation of property and equipment
Net deferred tax asset
Valuation allowance
Total net deferred tax (liability)
2017
2016
$
$
$
68,631
9,017
366,176
(231,543)
239,549
(366,176)
(153,895) $
93,829
26,259
303,784
(333,455)
90,417
(303,784)
(213,367)
The Tax Cuts and Jobs Act was enacted on December 22, 2017. The legislation significantly changes United States tax law by, among other things, reducing
our corporate income tax rates from 34% to 21%, effective January 1, 2018. As a result of the reduction in the corporate income tax rate, the Company
revalued its net deferred tax liabilities at December 31, 2017 and recognized a $90,980 tax benefit in the Company’s consolidated statement of operations
At December 31, 2017 and 2016, the Company has a net operating loss carryforward with the state of Alabama. The net operating losses of $5,636,482 and
$4,676,600 expire between 2020 and 2031. The Company does not expect to be able to utilize these losses and has recorded a valuation allowance for the full
amount of the net operating losses.
Note 9 – Related party transactions:
During 2017, as in previous years, the Company sold products to companies affiliated with Peter G. Dornau, who is the Company’s Chairman, President and
Chief Executive Officer. The affiliated companies distribute the products outside of the United States and Canada. The Company also provides administrative
services to these companies. Sales to the affiliated companies aggregated approximately $2,070,000 and $1,850,000 during the years ended December 31,
2017 and 2016, respectively, and fees for administrative services aggregated approximately $884,000 and $735,000 (including approximately $120,000 and
$115,000 to reimburse the Company for business related expenditures that it made on behalf of the affiliated companies) during the years ended December
31, 2017 and 2016, respectively. The Company had accounts receivable from the affiliated companies in connection with the product sales and
administrative services aggregating approximately $1,584,000 and $1,190,000 at December 31, 2017 and 2016, respectively.
F-13
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 30
03/30/2018 02:52 PM
An entity that is owned by the Company’s Chairman, President and Chief Executive Officer provides several services to the Company. Under this
arrangement, the Company paid the entity $42,000 for research and development services for each of the years ended December 31, 2017 and 2016. The
research and development expenses are included in the Company’s statements of operations for the years ended December 31, 2017 and 2016 as a selling and
administrative expense. In addition, during the year ended December 31, 2017, the Company paid this entity $64,250 for providing charter boat services for
marketing events for the Company’s nonaffiliated customers. The charter boat services are included in the Company’s statement of operations for the year
ended December 31, 2017 as an advertising and promotion expense. During the year ended December 31, 2016, the Company paid this entity $25,000 for the
production of television commercials and $9,000 for providing charter boat services for entertainment of the Company’s nonaffiliated customers.
The Company leases office and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and Chief Executive
Officer. See Note 10 for a description of the lease terms.
A director of the Company is Regional Executive Vice President of an insurance broker through which the Company has sourced most of its general and
liability insurance and, commencing in 2017, its health insurance. During the years ended December 31, 2017 and 2016, the Company paid an aggregate of
approximately $1,235,000 and $697,000, respectively, in insurance premiums on policies obtained through the insurance broker.
Note 10 – Commitments and contingencies:
The Company leases its executive offices and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and Chief
Executive Officer. The lease, as extended, expires on December 31, 2023. The lease requires an annual minimum base rent of $94,800 and provides for a
maximum annual 2% increase in subsequent years, although the entity has not raised the minimum rent since the Company entered into a previous lease
agreement in 1998. Additionally, the leasing entity is entitled to reimbursement of all taxes, assessments, and any other expenses that arise from ownership.
Each of the parties to the lease has agreed to review the terms of the lease every three years at the request of the other party. Rent expense under the lease
was approximately $97,000 for each of the years ended December 31, 2017 and 2016. The rent expense is included in the Company’s statements of
operations as a selling and administrative expense.
The Company also leases a 15,000 square foot warehouse from an unrelated third party in Montgomery, Alabama near its Kinpak manufacturing facility for
the purpose of fabricating and assembling brushes used for cleaning boats, automobiles and recreational vehicles. The lease commenced on August 1, 2016
and expires on July 31, 2018. The Company pays monthly rent of $4,375 under the lease.
The following is a schedule of minimum future rentals on the Company’s non-cancelable operating leases.
Year ending December 31,
2018
2019
2020
2021
2022
Thereafter
Total
Note 11 - Stock options and awards:
$
$
126,689
97,985
99,945
101,944
103,983
106,062
636,608
On May 29, 2015, the Company’s shareholders approved the Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan (the “Plan”). The Plan provides for
grants of several types of awards at the discretion of the Equity Grant Committee of the Company’s Board of Directors, including stock options, stock units,
stock awards, stock appreciation rights and other stock based awards. The Plan authorizes the issuance of 630,000 shares of Company common stock, subject
to anti-dilution adjustments upon the occurrence of certain events affecting the common stock During the years ended December 31, 2017 and 2016, the
Company issued stock awards under the Plan aggregating 79,100 and 142,000 shares of common stock, respectively, to officers, key employees, directors
and a consultant of an affiliated company. Following the withholding of an aggregate of 5,500 and 3,918 shares of common stock, respectively, in connection
with a net exercise feature of the Plan, 73,600 and 138,082 shares were delivered to the award recipients, for the years ended December 31, 2017 and 2016,
respectively. At December 31, 2017, 343,400 shares remained available for future issuance under the Plan. The shares vested immediately upon issuance and
were fully expensed in the period in which they were awarded. Compensation expense related to the stock awards was $324,145 and $305,780 for the years
ended December 31, 2017 and 2016, respectively. The Company withheld shares in 2017 and 2016 that had a value of $22,468 and $8,424, respectively, for
income tax withholding related to the awards. As a result of the adoption of the Plan, no further stock awards will be made under the Company’s equity
compensation plans previously approved by its shareholders (the “Prior Plans”).
F-14
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 31
03/30/2018 02:52 PM
Prior to the May 29, 2015 effective date of the Plan, stock options were granted under the Prior Plans. Only non-qualified options granted under the Prior
Plans were outstanding on December 31, 2017. Outstanding non-qualified options were granted to outside directors, have a 10-year term from the date of
grant and are immediately exercisable. The last tranche of non-qualified options previously granted terminate on April 25, 2020. There was no
compensation expense attributable to stock options recognized during the years ended December 31, 2017 and 2016, and at December 31, 2017 and 2016,
there was no unrecognized compensation cost related to share based compensation arrangements
During 2017, stock options to purchase an aggregate of 40,000 shares were exercised. The Company received a total of $26,400, withheld 5,957 shares in
connection with the net exercise feature of the stock options and delivered an aggregate of 34,043 shares to the option holders who exercised their options.
During 2016, stock options to purchase an aggregate of 30,000 shares were exercised. The Company received a total of $21,600, withheld 4,519 shares in
connection with the net exercise feature of the stock options and delivered an aggregate of 25,481 shares to the option holders who exercised their options.
The following tables provide information regarding outstanding options under the Company’s stock option plans at December 31, 2017 and 2016. As used in
the table below, “2002 NQ” refers to the Company’s 2002 Non-Qualified Stock Option Plan and “2008 NQ” refers to the Company’s 2008 Non-Qualified
Stock Option Plan.
At December 31, 2017:
Plan
2008 NQ
2008 NQ
At December 31, 2016:
Plan
2002 NQ
2008 NQ
2008 NQ
Date
Granted
Options
Outstanding
Exercisable
Options
1/11/09
4/26/10
40,000
20,000
60,000
40,000
20,000
60,000
Exercise Price
0.69
2.07
1.15
$
Expiration
Date
1/10/19
4/25/20
Date
Granted
Options
Outstanding
Exercisable
Options
12/17/07
1/11/09
4/26/10
40,000
40,000
20,000
100,000
40,000
40,000
20,000
100,000
Exercise Price
1.32
0.69
2.07
1.22
$
Expiration
Date
12/16/17
1/10/19
4/25/20
Weighted
Average
Remaining
Life
1.0
2.4
1.5
Weighted
Average
Remaining
Life
1.0
2.1
3.4
1.9
The following table provides information relating to stock option transactions during the years ended December 31, 2017 and 2016:
Options outstanding beginning of the year
Options exercised
Total
2017
2016
Weighted
Average
Exercise
Price
1.22
1.32
1.15
Shares
100,000
(40,000)
60,000
$
$
Weighted
Average
Exercise
Price
1.19
1.08
1.22
Shares
130,000
(30,000)
100,000
$
$
F-15
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 32
03/30/2018 02:52 PM
Note 12 – Major customers:
The Company had net sales to each of two major customers that constituted in excess of 10% of the Company’s consolidated net sales for each of the years
ended December 31, 2017 and 2016. Net sales to each of these two customers represented approximately 22.4% and 11.6% of consolidated net sales for
2017 and approximately 20.3% and 12.7% of consolidated net sales for 2016, respectively.
Note 13 – Litigation expense:
During the year ended December 31, 2016, the Company was engaged in litigation with a competitor in which each of the Company and the competitor
claimed that the other was engaged in false advertising and related violations of law. Following a trial in which it was determined that neither party was liable
to the other, the matter was concluded. The Company incurred professional fees and expenses relating to this matter of $1,146,000 during the year ended
December 31, 2016. This amount is included in the Company’s statement of operations for the year ended December 31, 2016 as selling and administrative
expenses. The matter concluded in 2016, and no expenses related to this litigation were incurred during the year ended December 31, 2017.
Note 14 – Earnings per share:
Basic earnings per share are calculated by dividing net income by the weighted average number of shares outstanding during the reporting period. Diluted
earnings per share reflect additional dilution from potential common stock issuable upon the exercise of outstanding stock options. The following table sets
forth the computation of basic and diluted earnings per common share, as well as a reconciliation of the weighted average number of common shares
outstanding to the weighted average number of shares outstanding on a diluted basis.
Earnings per common share –Basic
Net income
Weighted average number of common shares outstanding
Earnings per common share – Basic
Earnings per common share – Diluted
Net income
Weighted average number of common shares outstanding
Dilutive effect of employee stock-based awards
Weighted average number of common shares outstanding - assuming dilution
Earnings per common share - Diluted
Years Ended
December 31,
2017
2016
2,603,534
$
2,095,171
9,190,429
9,059,966
0.28
$
0.23
2,603,534
$
2,095,171
9,190,429
9,059,966
63,373
9,253,802
56,550
9,116,516
0.28
$
0.23
$
$
$
$
The Company had no stock options outstanding at December 31, 2017 and 2016, respectively that were anti-dilutive and therefore not included in the diluted
earnings per common share calculation.
Note 15 – Cash Dividends:
On April 13, 2017, the Company’s Board of Directors declared a special cash dividend of $0.06 per common share payable on May 11, 2017 to all
shareholders of record on April 27, 2017. On April 27, 2017, there were 9,154,243 shares of common stock outstanding; therefore, dividends aggregating
$549,255 were paid on May 11, 2017.
On March 25, 2016, the Company’s Board of Directors declared a special cash dividend of $0.06 per common share payable on April 26, 2016 to all
shareholders of record on April 12, 2016. On April 12, 2016, there were 9,008,855 shares of common stock outstanding; therefore, dividends aggregating
$540,531 were paid on April 26, 2016.
F-16
OBCI, INC. ANNUAL REPORT 2017 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 33
03/30/2018 02:52 PM
Note -16 – Recent Accounting Pronouncements:
Accounting Guidance Adopted by the Company
In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-11, “Inventory” (Topic 330) to
simplify the measurement of inventory subsequent to its initial measurement and to more closely align the measurement of inventory under GAAP with the
measurement of inventory under International Financial Reporting Standards. The guidance in ASU 2015-11 (which applies to inventory that is measured
using the first-in, first-out (FIFO) or average cost method, but not to inventory measured using the last-in, first-out (LIFO) or the retail inventory method),
requires subsequent measurement of inventory to be at the lower of cost and net realizable value (rather than the lower of cost or market, as under previous
guidance). Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal,
and transportation. The Company adopted this guidance effective January 1, 2017. The adoption of this guidance did not have a material impact on the
Company’s financial statements.
Accounting Guidance Not Yet Adopted by the Company
In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606).” ASU 2014-09, which has been modified on several
occasions, provides new guidance designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital
markets. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an
amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance also requires
disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The new guidance is effective
for us beginning January 1, 2018. The Company will use the full retrospective method. Management has evaluated our current revenue recognition process
and reviewed active customer agreements and assessed that under ASU 2014-09 our performance obligation to our customers is satisfied when the goods are
shipped and title of the goods is transferred, or in the case in which our inventory is held in consignment upon sale to a third party, when we are notified of
sales by the consignee. The timing of our revenue recognition will not change, however certain allowances given to customers primarily cooperative
advertising will be considered a reduction of revenue instead of an advertising and promotion expense. This reclassification will not affect net income.
In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (“ASU 2016-02”), “Leases.” Generally, under ASU 2016-02, lessees will be
required to recognize, at the commencement date of each lease having a term of more than 12 months, both a lease liability, which is a lessee’s obligation to
make lease payments arising from a lease, initially measured at the present value of the lease payments, and a right-to-use asset, which is an asset that
represents the lessee’s right to use or control the use of the underlying asset for the lease term. Leases will be classified as either finance or operating; the
classification will affect the manner of reporting expenses and cash flows. The new guidance is effective for fiscal years, and interim periods within those
years, beginning after December 15, 2018, with early adoption permitted. The guidance must be adopted using a modified retrospective transition approach
for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The guidance provides
certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s financial statements.
In November 2016, the FASB issued ASU 2016-18, which requires entities to present the changes in total cash, cash equivalents, restricted cash and
restricted cash equivalents in the statement of cash flows. The new guidance also requires a reconciliation of the totals in the statement of cash flows to the
related captions in the balance sheet if restricted cash and restricted cash equivalents are presented in a different line item in the balance sheet. The
amendments of this Update, which should be applied using a retrospective transition method to each period presented, are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard will change the
presentation in the consolidated statements of cash flows.
In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which simplifies the accounting for goodwill impairments by
eliminating step 2 from the goodwill impairment test. Instead, if “the carrying amount of a reporting unit exceeds its fair value, an impairment loss shall be
recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.” The guidance is effective for fiscal
years beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this new standard will
have on its consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13 Financial Instruments – Credit Losses which replaces the incurred loss model with a current expected credit
loss (“CECL”) model. The CECL model applies to financial assets subject to credit losses and measured at amortized cost and certain off-balance sheet
exposures. Under current U.S. GAAP, an entity reflects credit losses on financial assets measured on an amortized cost basis only when losses are probable
and have been incurred, generally considering only past events and current conditions in making these determinations. ASU 2016-13 prospectively replaces
this approach with a forward-looking methodology that reflects the expected credit losses over the lives of financial assets, starting when such assets are first
acquired. Under the revised methodology, credit losses will be measured based on past events, current conditions and reasonable and supportable forecasts
that affect the collectability of financial assets. ASU 2016-13 also revises the approach to recognizing credit losses for available-for-sale securities by
replacing the direct write-down approach with the allowance approach and limiting the allowance to the amount at which the security’s fair value is less than
the amortized cost. In addition, ASU 2016-13 provides that the initial allowance for credit losses on purchased credit impaired financial assets will be
recorded as an increase to the purchase price, with subsequent changes to the allowance recorded as a credit loss expense. ASU 2016-13 also expands
disclosure requirements regarding an entity’s assumptions, models and methods for estimating the allowance for credit losses. The amendments of this
Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted as of
January 1, 2019. The Company is currently evaluating the impact the adoption of this new standard will have on its consolidated financial statements.
Note -17 – Subsequent Event:
On March 19, 2018, the Company’s Board of Directors declared a special cash dividend of $0.06 per common share payable on April 16, 2018 to all
shareholders of record on April 2, 2018. At the time of the filing of this report there were 9,254,580 shares of common stock outstanding; therefore,
dividends aggregating $555,275 will be paid on April 16, 2018.
F-17
AMERICAN MADE SINCE 1973 f10k2017_oceanbiochem.htm
Edgar Agents LLC
Form Type: 10-K
OCEAN BIO-CHEM, INC.
Page 34
03/30/2018 02:52 PM
Unless otherwise noted, the file number of each referenced filing is 0-11102
EXHIBIT INDEX
Exhibit No.
3.1.1
3.1.2
3.2
10.1.1
10.1.2
10.1.3
*10.1.4
10.2
10.3.1
10.3.2
10.3.3
10.3.4
10.4
10.5
10.6.1
10.6.2
10.6.3
*21
*23
*31.1
*31.2
*32.1
*32.2
101
Articles of Incorporation and amendments through May 20, 1994 (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on
Form 10-K for the year ended December 31, 2010).
Articles of Amendment to the Articles of Incorporation, as filed on June 13, 2012 (incorporated by reference to Exhibit 3.1.2 to the Company's
Annual Report on Form 10-K for the year ended December 31, 2012).
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the
Securities and Exchange Commission on December 5, 2011).
Business Loan Agreement, dated August 31, 2017, between the Company and Regions Bank (the “Business Loan Agreement”) (incorporated
by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017).
Promissory Note, dated August 31, 2017, issued by the Company to Regions Bank in connection with the revolving line of credit under the
Business Loan Agreement (the “Promissory Note”) (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form
10-Q for the quarter ended September 30, 2017).
Letter, dated August 31, 2017, from Regions Bank to the Company, regarding certain terms under the Business Loan Agreement and the
Promissory Note (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September
30, 2017).
Letter, dated December 20, 2017, from Regions Bank to the Company, regarding certain terms of the Business Loan Agreement.
Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan, as amended (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly
Report on Form 10-Q, filed with the Securities and Exchange Commission on August 12, 2016).
Form of Industrial Development Revenue Bond (Kinpak Inc. Project) Series 2017 (incorporated by reference to Exhibit 99.1 to the Company’s
Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 2, 2017).
Second Restated Lease Agreement, dated as of September 1, 2017, between The Industrial Development Board of the City of Montgomery and
KINPAK, Inc. (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K, filed with the Securities and
Exchange Commission on October 2, 2017).
Mortgage, Security Agreement and Assignment of Rents and Leases, dated as of September 1, 2017, provided by The Industrial Development
Board of the City of Montgomery and KINPAK, Inc. (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form
8-K, filed with the Securities and Exchange Commission on October 2, 2017).
Guaranty Agreement, dated as of September 1, 2017, provided by Ocean Bio-Chem, Inc. and its consolidated subsidiaries party
thereto (incorporated by reference to Exhibit 99.4 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange
Commission on October 2, 2017).
Ocean Bio-Chem, Inc. 2002 Non-Qualified Stock Option Plan, as amended (incorporated by reference to Exhibit 99.2 to the Company’s
Registration Statement on Form S-8 (File No. 333-176268), filed with the Securities and Exchange Commission on August 12, 2011).
Ocean Bio-Chem, Inc. 2008 Non-Qualified Stock Option Plan, as amended (incorporated by reference to Exhibit 99.5 to the Company’s
Registration Statement on Form S-8 (File No. 333-176268), filed with the Securities and Exchange Commission on August 12, 2011).
Net Lease, dated May 1, 1998, between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to Exhibit 10.14 to the
Company’s Annual Report on Form 10-K for the year ended December 31, 2004).
Renewal of Lease, dated May 1, 2008, between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to Exhibit 10.24 to the
Company’s Annual Report on Form 10-K for the year ended December 31, 2008).
Amendment Number Two to Net Lease, dated May 16, 2013, between Star Brite Distributing, Inc. and PEJE, Inc. (incorporated by reference to
Exhibit 10.13 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013).
List of Subsidiaries
Consent of EisnerAmper LLP
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act and 18 U.S.C. Section 1350.
Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act and 18 U.S.C. Section 1350.
The following materials from Ocean Bio-Chem Inc.’s Annual Report on Form 10-K for the year ended December 31, 2017, formatted in
XBLR (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets at December 31, 2017 and December 31, 2016; (ii)
Consolidated Statements of Operations for the years ended December 31, 2017 and 2016; (iii) Consolidated Statements of Comprehensive
Income for the years ended December 31, 2017 and 2016; (iv) Consolidated Statements of Changes in Shareholders Equity for the years ended
December 31, 2017 and 2016, (v) Consolidated Statements of Cash Flows for the years ended December 31, 2017 and 2016 and (vi) Notes to
Consolidated Financial Statements.
* Filed herewith.
E-1
OBCI, INC. ANNUAL REPORT 2017 f10k2017ex10-1iv_oceanbio.htm
Edgar Agents LLC
Form Type: EX-10.1.4
OCEAN BIO-CHEM, INC.
Page 1
03/30/2018 02:52 PM
Exhibit 10.1.4
AMERICAN MADE SINCE 1973 f10k2017ex10-1iv_oceanbio.htm
Edgar Agents LLC
Form Type: EX-10.1.4
OCEAN BIO-CHEM, INC.
Page 2
03/30/2018 02:52 PM
OBCI, INC. ANNUAL REPORT 2017 f10k2017ex21_oceanbiochem.htm
Edgar Agents LLC
Form Type: EX-21
OCEAN BIO-CHEM, INC.
The following is a list of the Registrant’s subsidiaries:
Name
Star brite Distributing, Inc.
Star brite Distributing Canada, Inc.
D & S Advertising Services, Inc.
Star brite StaPut, Inc.
Star brite Service Centers, Inc.
Star brite Automotive, Inc.
KINPAK, Inc.
OdorStar Technology, LLC
Jurisdiction
of Organization
Florida
Florida
Florida
Florida
Florida
Florida
Alabama
Florida
Page 1
03/30/2018 02:52 PM
EXHIBIT 21
Ownership %
100
100
100
100
100
100
100
100
AMERICAN MADE SINCE 1973 f10k2017ex23_oceanbiochem.htm
Edgar Agents LLC
Form Type: EX-23
OCEAN BIO-CHEM, INC.
Page 1
03/30/2018 02:52 PM
EXHIBIT 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements of Ocean Bio-Chem, Inc. (the “Company”) on Form S-8 (Nos. 333-176268 and
333-204520) of our report dated March 30, 2018 on our audits of the consolidated financial statements of the Company as of December 31, 2017 and 2016
and for each of the years then ended, which report is included in this Annual Report on Form 10-K filed March 30, 2018.
/s/ EISNERAMPER LLP
EISNERAMPER LLP
Ft. Lauderdale, Florida
March 30, 2018
OBCI, INC. ANNUAL REPORT 2017 f10k2017ex31-1_oceanbiochem.htm
Edgar Agents LLC
Form Type: EX-31.1
OCEAN BIO-CHEM, INC.
I, Peter G. Dornau, certify that:
CERTIFICATION
Page 1
03/30/2018 02:52 PM
EXHIBIT 31.1
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Ocean Bio-Chem, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
Dated: March 30, 2018
/s/ Peter G. Dornau
Peter G. Dornau
Chairman of the Board, President and
Chief Executive Officer
AMERICAN MADE SINCE 1973 f10k2017ex31-2_oceanbiochem.htm
Edgar Agents LLC
Form Type: EX-31.2
OCEAN BIO-CHEM, INC.
I, Jeffrey S. Barocas, certify that:
CERTIFICATION
Page 1
03/30/2018 02:52 PM
EXHIBIT 31.2
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Ocean Bio-Chem, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
Dated: March 30, 2018
/s/ Jeffrey S. Barocas
Jeffrey S. Barocas
Vice President,Chief Financial Officer
OBCI, INC. ANNUAL REPORT 2017 f10k2017ex32-1_oceanbiochem.htm
Edgar Agents LLC
Form Type: EX-32.1
OCEAN BIO-CHEM, INC.
Page 1
03/30/2018 02:52 PM
EXHIBIT 32.1
CERTIFICATION PURSUANT TO RULE 13a-14(b)
UNDER THE SECURITIES EXCHANGE ACT AND 18 U.S.C. 1350
I, Peter G. Dornau, Chief Executive Officer of Ocean Bio-Chem, Inc. (the “Company”), hereby certify that, based on my knowledge:
1. The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (the “Report”) fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
By:
/s/ Peter G. Dornau
Peter G. Dornau
Chairman of the Board, President and
Chief Executive Officer
Dated: March 30, 2018
AMERICAN MADE SINCE 1973 f10k2017ex32-2_oceanbiochem.htm
Edgar Agents LLC
Form Type: EX-32.2
OCEAN BIO-CHEM, INC.
Page 1
03/30/2018 02:52 PM
EXHIBIT 32.2
CERTIFICATION PURSUANT TO RULE 13a-14(b)
UNDER THE SECURITIES EXCHANGE ACT AND 18 U.S.C. 1350
I, Jeffrey S. Barocas, Chief Financial Officer of Ocean Bio-Chem, Inc. (the “Company”), hereby certify that, based on my knowledge:
1. The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (the “Report”) fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
By:
/s/ Jeffrey S. Barocas
Jeffrey S. Barocas
Vice President, Chief Financial Officer
Dated: March 30, 2018
OBCI, INC. ANNUAL REPORT 2017 NVESTOR INFORMATION
NASDAQ STOCK SYMBOL OBCI
Stock Transfer Agent
Computershare
P.O. Box 30170
College Station, Texas 77842 -3179
General Counsel
Berger Singerman, LLP
350 East Las Olas Boulevard
Fort Lauderdale, Florida 33324
Auditors
EisnerAmper
900 South Pine Island Road
Fort Lauderdale, Florida 33301
Reports and Publications
A free copy of the Company’s 2017
Form 10-K filed with the Securites
and Exchange Commission can
be obtained upon written request to:
Corporate Relations Department
4041 SW 47th Avenue
Fort Lauderdale, Florida 33314
COMMON STOCK
MARKET INFORMATION
The following table sets forth high and low sales prices
of the Common Stock of Company as reported on the
NASDAQ Capital Market for each calendar quarter
in 2017 and 2016:
2017
2016
High
$5.15
$5.65
$5.47
$5.71
Low
$3.66
$3.69
$3.51
$3.98
High
$2.66
$2.57
$3.17
$4.35
Low
$1.93
$2.08
$2.02
$2.61
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
OCEAN BIO-CHEM, INC.
BOARD OF DIRECTORS
Peter G. Dornau
Jeffrey S. Barocas
Gregor M. Dornau
William W. Dudman
James M. Kolisch
Kimberly A. Krause*
Diana Mazuelos Conard*
John B. Turner*
* A member of audit and equity grant committees
OFFICERS OF
OCEAN BIO-CHEM, INC.
Peter G. Dornau
President and Chief Executive Officer
Jeffrey S. Barocas
Vice President, Chief Financial Officer
Gregor M. Dornau
Executive Vice President of Sales and Marketing
William W. Dudman
Vice President, Chief Operating Officer,
Coorporate Secretary
OFFICERS OF STAR BRITE, INC.
Peter G. Dornau
President and Chief Executive Officer
Jeffrey S. Barocas
Vice President, Chief Financial Officer
Natalie S. Cuomo
Vice President of Customer Service
Gregor M. Dornau
Executive Vice President of Sales and Marketing
William W. Dudman
Vice President, Chief Operating Officer
Marc A. Emmi
Senior Vice President of Sales
Justin L. Gould
Vice President of Technology
George W. Lindsey, Jr.
Vice President of Marketing
Victor G. Phillpotts
Vice President of Business Development
4041 SW 47th Avenue • Fort Lauderdale, Florida 33314
Tel:(954) 587-6280 • (800) 327-8583 • Fax:(954) 587-2813
WWW.OCEANBIOCHEM.COM • WWW.STARBRITE.COM
WWW.STARTRON.COM • WWW.NOS-GUARD.COM
WWW.ODORSTAR.COM • WWW.PERFORMACIDE.COM
AMERICAN MADE SINCE 1973 CORPORATE OFFICES • FORT LAUDERDALE, FLORIDA
OCEAN BIO-CHEM, INC. MANUFACTURING CAPABILITIES
MANUFACTURING & DISTRIBUTION FACILITIES
MONTGOMERY, ALABAMA
QUALITY CONTROL
FILLING
DISTRIBUTION
Ocean Bio-Chem, Inc.’s main manufacturing and distribution
facility is its wholly-owned subsidiary, Kinpak, Inc., located
on a 20 acre site in Montgomery, Alabama. In addition to
manufacturing Star brite® products, Kinpak also manufactures
numerous items under private label programs. The facility’s
200,000 sq. ft. manufacturing, blending, packing and distribution
center features a 500,000 gallon tank farm, as well as a fully-
equipped R&D laboratory, a facility for the production of chlorine
dioxide products and a quality control center that performs
quality audits for each phase of the production process.
The plant has 300,000 gallons of blending capacity plus
multiple blow-molding machines that produce custom PVC and
HDPE bottles in various colors and shapes. There are ten fully-
automated high-speed liquid filling lines, pail lines, a drum filling
line, bulk load filling lines, plus grease filling lines capable of filling
containers ranging in size from 1 ounce to 55 gallons at speeds of
up to 120 gallons per minute.
Finished goods are secured by automatic case packers, case
sealers and palletizers. In addition to a line of truck loading
docks, the facility has a rail spur capable of handling 20 railcars.
Star brite® and Star Tron® products are available at marine,
automotive, power sports, outdoor power equipment and
hardware stores, as well as at sporting goods stores, agriculture
and RV stores worldwide.
WWW.OCEANBIOCHEM.COM • WWW.STARBRITE.COM
WWW.STARTRON.COM • WWW.NOS-GUARD.COM
WWW.ODORSTAR.COM • WWW.PERFORMACIDE.COM
OBCI, INC. ANNUAL REPORT 2017